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II. Abstract (deutsch) 
MPL Defizienz beruht auf inaktivierenden Mutationen im Thrombopoietin 
(THPO) Rezeptor c-mpl, was zu der Erkrankung Kongenitale Amegakaryozytäre 
Thrombozytopenie (CAMT) führt. MPL spielt eine Schlüsselrolle in der Regulation von 
hämatopoetischen Stammzellen und Megakaryozyten. Mit dem Ziel eine Gentherapie für 
MPL Defizinz zu entwickeln, haben wir Mpl retroviral in einem murinen Knochenmark-
Transplantationsmodell überexprimiert. Nur einige Wochen nach der Transplantation 
entwickelten die Tiere eine Chronische Myeloproliferative Erkrankung (CMPD), welche 
sich im weiteren Verlauf zu einer Panzytopenie mit einem Myelodysplastisch-ähnlichen 
Syndrom (MDS) entwickelte. Mit Hilfe eines verkürzten Mpl Rezeptors, bei welchem ein 
Teil der intrazellulären Signaldomäne fehlte, konnten wir zeigen, dass die CMPD auf 
einer supra-physiologischen Signalaktivierung beruht. Weiterhin konnten wir den 
Mechanismus der Panzytopenie und MDS als einen dominant negativen Effekt erklären. 
Ein kleiner Teil der transplantierten Mäuse entwickelte eine erythroide Leukämie (3/27) 
ausgelöst durch Insertionsmutagenese.  
 Um eine umfassende Risikoabschätzung durchzuführen, konstruierten wir eine 
konstitutiv aktive Mpl Rezeptor Mutante (caMpl), welche hoch leukämogen war. Nur 
drei Wochen nach der Transplantation entwickelten die Mäuse erythroide und myeloide 
Leukämien. Die Leukämieentstehung war unabhängig von der Bindung des Liganden 
Thpo und reduzierte Expression des caMpl Proteins führte zu einer verlängerten 
Latenzzeit. Eine weitere caMpl Mutante, bei welcher die letzten drei Tyrosinaminosäuren 
fehlten, die wichtig für die Aktivierung des Ras-Signalwegs sind, war nicht leukämisch.  
 Wir konstruierten optimale Vektoren für eine Gentherapie aus 
selbstinaktivierenden (SIN) Vektoren und dem niedrig und linienspezifisch 
exprimierenden Mpl Promotor (MplP). Tiere, die mit genkorrigierten Mpl-/- Zellen 
transplantiert wurden, zeigten keine Nebenwirkung bei normaler Teilnahme der 
korrigierten Mpl-/- Zellen an der Hämatopoese.  
 Wir konnten dosislimitierende Nebenwirkungen der Gentherapie für CAMT 
(CMPD, MDS, Panzytopenie und Leukämie) identifizieren und zeigen, dass 
physiologisch genkorrigierte Mpl-/- Zellen nach Transplantation langzeitlich anwachsen.  
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III. Abstract (englisch) 
MPL deficiency is based on inactivating mutations in the thrombopoietin (THPO) 
receptor c-mpl resulting in a disorder called congenital amegakaryocytic thrombo-
cytopenia (CAMT). MPL is a key regulator of hematopoietic stem cells and is responsible 
for megakaryocyte differentiation and platelet production. With the aim of developing a 
curative gene therapy, we retrovirally overexpressed Mpl in a murine bone marrow 
transplantation (BMT) model. Only a few weeks after transplantation, mice developed a 
chronic myeloproliferative disease (CMPD) that developed further into pancytopenia and 
myelodysplastic-like syndrome (MDS). With a truncated Mpl mutant lacking the 
signaling domain, we could show that CMPD was caused by supra-physiological 
signaling. In addition, we could describe the mechanism of pancytopenia and MDS-like 
disorder as a dominant negative effect resulting from Thpo trapping. Another serious 
adverse event of retroviral vector-mediated Mpl expression was erythroleukemia, which 
developed in a minority of mice (3/27) and was induced by insertional mutagenesis.  
To perform an even broader risk assessment, we constructed a constitutively 
active Mpl receptor mutant (caMpl) that was highly leukemogenic. Animals developed 
erythro- or myeloid leukemias only three weeks after BMT. We could show that the 
leukemia development was independent of Thpo binding and that a reduced transgene 
expression level prolonged the latency. Interestingly, a truncated receptor mutant of 
caMpl lacking the last three tyrosine residues important for activation of Ras signaling 
did not induce leukemia.  
We constructed optimized vectors for the gene therapy of CAMT with self in-
activating (SIN) constructs. To reduce the expression level and to mediate differentiation-
specific expression of the transgene, we used the endogenous Mpl promoter (MplP) to 
drive expression of wild type Mpl. Gene-corrected Mpl-/- BM cells transduced with the 
SIN.MplP.wtMpl vector showed engraftment after BMT and normal participation of 
these gene-corrected Mpl-/- cells in hematopoiesis without serious adverse events.  
Taken together we identified the challenges of Mpl gene therapy (CMPD, MDS, 
pancytopenia and leukemia) and showed that gene-corrected Mpl-/- cells could be 
engrafted in a competitive in vivo assay after BMT.  
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1.  Introduction 
 
1.1. Hematopoietic stem cells are a small population of pluripotent cells  
Hematopoietic stem cells (HSC) represent the earliest and most undifferentiated blood 
cells. They are pluripotent stem cells, because they are able to give rise to all 
hematopoietic lineages the peripheral blood (PB) cells, but typically not to other tissue 
organs. HSC mostly reside in the bone marrow (BM) niche (Yin and Li, 2006); only 
small numbers circulate in the PB. Cytokine and chemokine-mediated interaction of HSC 
with their niche is required for hematopoiesis (Avecilla et al., 2004). It is estimated that 
about 1 in 100,000 BM cells is a true HSC. Despite their low frequency, HSC have the 
ability to regenerate hematopoiesis with their unique ability to differentiate and to self-
renew. When undergoing the process of self-renewal, the HSC divide but remain in the 
undifferentiated state. HSC have a slow division rate and about 20% of all divisions are 
asymmetrical (Ho and Wagner, 2007) which means that one daughter cell retains the stem 
cell character whereby the other one differentiates (Giebel et al., 2006; Leary et al., 1985; 
Mayani et al., 1993). Since the development of monoclonal antibodies (mAb) against 
specific cell surface markers and fluorescence-activated cell sorting (FACS), it is possible 
to characterize and purify stem cell fractions. Murine HSC are enriched in the lineage-
negative (Lin-) fraction which is defined as Gr1-, CD11b- (myeloid markers), TER119- 
(erythroid marker), CD5- (B-cell marker) and CD45R- (naïve T-cell and leukocyte 
marker).  To further purify HSC, they can be sorted in the Lin- fraction for Sca1+ and 
ckit+ cells which comprise the LSK fraction. The LSK fraction can again be further 
separated and contains the long-term (LT) and short-term (ST) repopulating HSC 
(Morrison and Weissman, 1994; Osawa et al., 1996; Smith et al., 1991; Uchida and 
Weissman, 1992).  
Since HSC can reconstitute all blood lineages, their transfer is used in many therapeutic 
protocols. Disorders which are regularly treated by BM transplantation (BMT) are 
leukemia, lymphoma, inborn metabolic disorders and inherited anemias (Muraoka et al., 
2005; Steward and Jarisch, 2005; Thomas et al., 1957).  
 
 
 
 
Introduction   
16 
16
1.2. Hematopoiesis is the production of all peripheral blood cells 
The process of HSC giving rise to all hematopoietic lineages is described as 
hematopoiesis. The HSC thereby differentiate into two arms, common myeloid 
progenitors (CMP) and common lymphoid progenitors (CLP) (Akashi et al., 2000; 
Kaushansky, 2006b; Kondo et al., 1997). CMP have the potential to build the red cells, 
platelets and the white blood cells and thus develop into megakaryocyte erythroid 
progenitors (MEP) and granulocyte monocyte progenitors (GMP).  
 
 
 
Figure 1.1: General model of hematopoiesis (Kaushansky, 2006b). The blood cell development is emanating from HSC 
and controlled by several factors. HSC have the potential to self-renew or differentiate into blood progenitors. These 
processes are mediated by several cytokines. Abbreviations: HSC hematopoietic stem cell, CMP common myeloid 
progenitor, CLP common lymphoid progenitor, MEP megakaryocyte erythroid progenitor, GM granulocyte progenitor, 
TNK T-cells and natural killer cells, BCP B-cell progenitor, MkP megakaryocyte progenitor, EP erythroid progenitor, MP 
monocyte progenitor, GP granulocyte progenitor, TCP T-cell progenitor, NKP natural killer cell progenitor, IL interleukin, 
TPO thrombopoietin, SCF stem-cell factor, M-CSF macrophage colony-stimulating factor, GM-CSF granulocyte-
macrophage CSF, EPO erythropoietin. 
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GMP finally differentiate via other precursors (monocyte precursor, MP and granulocyte 
precursor, GP) into mature monocytes and granulocytes (divided into neutrophils, 
eosinophils and basophils). Further differentiation of MEP results in erythroid precursors 
(EP) and mature red blood cells (erythrocytes) and in megakaryocyte precursors (MkP) 
and megakaryocytes (Mk) which produce all blood platelets (PLT, thrombocytes) (Figure 
1.1).  
Megakaryocytes constitute less than 1% of the myeloid cell mass in the BM. However, 
their amount can increase during disease up to ten times. Mk are easily distinguished 
from other blood cells because of their increased size (~100 µm). The primary site for Mk 
is the BM. Lower amounts can also be found in the lung and in the PB. The structure of 
their nuclei is described as “horseshoe-shaped”. Known surface markers are CD34, 
CD41, CD42, CD61, CD51 and CD110 (MPL) (Kirito and Kaushansky, 2006; Pang et 
al., 2005). The Mk progenitors (megakaryoblasts) lose their capacity to divide but retain 
their ability for DNA replication (endoreduplication) and cytoplasmic maturation. Mk 
undergo multiple rounds of endomitosis which amplifies their DNA content. The nuclear 
envelope breaks down and the mitotic cycle is arrested during anaphase B. When the 
nuclear envelope reforms, the Mk nucleus is polyploid (multilobed nucleus). 
Polyploidization can reach from 4N, 8N, 16N up to 256N whereby 16N is the most 
common state in half of the Mk population (Deutsch and Tomer, 2006; Patel et al., 2005). 
Mk have a high concentration of ribosomes which are needed for platelet production. 
Proplatelets are formed by fragmentation from the membrane of mature Mk which then 
mature to platelets. Human Mk produce about 1011 platelets per day in steady-state 
hematopoiesis (Kaushansky, 2008). 
 
1.3. Hematopoietic cytokines and their receptors regulate hematopoiesis 
Many hematopoietic processes like proliferation, differentiation, apoptosis and self-
renewal are regulated by cytokines and their receptors. Cytokines are small protein 
molecules which float in the PB and are transferred to the hematopoietic organs. They are 
produced by cells of different organs such as the kidneys and the liver, by stromal cells or 
hematopoietic cells in the hematopoietic microenvironment. Cytokines can be produced 
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constitutively or inducibly. Inflammatory mediators or BM stromal cells can lead to 
inducible cytokine production (Kaushansky, 2006b) (Figure 1.2). 
 
 
 
Figure 1.2: Production of hematopoietic growth factors (Kaushansky, 2006). Cytokines are produced by different 
organs like the kidneys and liver. Thrombopoietin (blue arrows) is produced constitutively by the liver (accounting for 
approximately 50% of baseline thrombopoietin levels). The kidneys produce only a minority of the total THPO amount. 
The production also is inducible in the liver by inflammatory mediators and from BM stromal cells by thrombocytopenia. 
Abbreviations: G-CSF granulocyte colony stimulating factor. 
 
Hematopoietic growth factor–receptors of the hematopoietin cytokine receptor 
superfamily 1 are cell membrane-spanning protein molecules. Two receptor subunits can 
dimerize to one receptor. Ligand binding substantially changes the conformation of the 
receptor, bringing the cytoplasmic domains into close juxtaposition and allowing the 
tethered kinases to cross-phosphorylate (activate) each other. One of the first substrates 
for Janus kinase 2 (JAK2) are receptor tyrosine (Y) residues. Upon their phosphorylation 
(P), they serve as docking sites for adaptors, phosphatases, G-protein activators and lipid 
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kinases. Eventually, most of such signals affect nuclear transcription of antiapoptosis 
molecules, cell-cycle regulators, differentiation associated proteins and other growth 
factors and their receptors. With the binding to their receptor, cytokines are removed by 
internalization (THPO, G-CSF) or unused cytokines can be excreted in the urine like 
erythropoietin (EPO). Cytokines, their receptors and downstream signal cascades play a 
pivotal role in different human neoplasias (Steelman et al., 2004) (Figure 1.3). 
 
 
 
Figure 1.3: Hematopoietic growth factor receptor signaling (Kaushansky, 2006). Growth factor receptors of the 
hematopoietin cytokine receptor super family 1 are composed of two subunits (monomers). Ligand binding changes the 
conformation of the receptor and results in cross-phosphorylation (activation). Janus kinas 2 (JAK2) phosphorylates (P) 
tyrosine (Y) residues. Abbreviations: SHC Src homology containing, GRB2 growth factor receptor–bound protein 2, GAB 
Grb binding, IRS insulin-receptor substrate, SHP2 Shc homology domain containing phosphatase, SOS son of sevenless, 
PI3K phosphoinositol 3-kinase, STAT signal transducer and activator of transcription 3 and 5, PI3,4,5P phosphoinositol 
3,4,5-phosphate, Ras small guanine nucleotide–binding protein, AKT serine/threonine protein kinase, MAPK p38 mitogen-
activated protein kinase, ERK extracellular response–stimulated kinase, P-FOX phosphatase forkhead, P-GSK3β 
phosphatase glycogen synthase kinase 3β, BCLXL nuclear transcription of antiapoptosis molecules, cyclins cell-cycle 
regulators, HGF hematopoietic growth factor.  
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1.4. The cytokine receptor MPL is activated by its ligand thrombopoietin  
The cytokine receptor MPL was identified in 1992 (Vigon et al., 1992) and its ligand 
THPO was found two years later (Bartley et al., 1994; Lok et al., 1994). MPL is named 
by the myeloproliferative leukemia virus (MPLV) (Wendling et al., 1986) which encodes 
the oncogene v-mpl (Souyri et al., 1990). THPO is produced by the liver and the kidneys 
(Qian et al., 1998). Therefore, an influence of THPO on hepatoblastoma cells is discussed 
(Romanelli et al., 2006). A steady-state amount of hepatic THPO is regulated by platelet 
MPL receptor–mediated uptake and destruction of the cytokine (Fielder et al., 1997). 
Upon binding to platelet’s MPL receptors, THPO is removed from the circulation and 
destroyed, which reduces THPO levels in the PB. Thrombocytopenia or inflammation can 
enhance the THPO production of the liver (Kaushansky, 2005) (Figure 1.4).  
 
 
Figure 1.4: Regulation of thrombopoietin levels (Kaushansky, 2005). A steady-state amount of thrombopoietin (THPO) 
is produced by the liver and the kidneys. It is regulated by platelet MPL receptor–mediated uptake and destruction of the 
cytokine. In the presence of inflammation THPO production by the liver is enhanced. Additionally, thrombocytopenia leads 
to enhanced marrow stromal cell production of thrombopoietin. 
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THPO is the only ligand of the MPL receptor. Upon ligand binding, receptor 
conformation shifts bringing the cytoplasmic domains together (Luoh et al., 2000; 
Miyakawa et al., 2000). The membrane-proximal Box 1 and Box 2 cytoplasmic domains 
constitutively bind Janus kinase 2 (JAK2) leading to cross-activation after ligand binding 
which initiates signal transduction. THPO activates both JAK2 and TYK2 (tyrosine 
kinase 2) but only JAK2 is essential for signaling and is the predominant isoform 
activated in primary Mk (Drachman et al., 1999). The active JAK kinase phosphorylates 
the receptor’s tyrosine residues and molecules that promote cell survival and 
proliferation, including the STATs (Signal transducer and activator of transcription 3 and 
5), PI3K (phosphoinositide-3 kinase) and MAPKs (mitogen-activated protein kinase). 
Furthermore, JAK2 phosphorylates molecules that limit cell signaling like SHP1 and 
SHIP1 phosphatases and SOCS. PI3K activates its downstream effector Akt (serine-
threonine protein kinase) (Bouscary et al., 2001; Miyakawa et al., 2001), and blocking 
this pathway inhibits THPO-induced cell survival and proliferation (Geddis et al., 2001). 
The pathways downstream of Akt in Mk and platelets include the transcription factor 
FOXO3a, the cell cycle inhibitor p27 and glycogen synthase kinase 3β (GSK3β). In 
addition to PI3K, THPO stimulates two of the MAPK pathways, p42/p44 (ERK1 and 
ERK2) and p38 MAPK (Drachman et al., 1997; Kirito et al., 2003). These events are 
mediated by binding and phosphorylation of Grb2, SHC and SOS and exchange of GDP 
for GTP on Ras (Rojnuckarin et al., 2001). The functional consequences of the events 
mediated by MAPK p38 include induction of the transcription factors HoxB4 and HoxA9 
which affects HSC expansion (Kirito et al., 2003; Kirito et al., 2004). ERK1/2 induce 
proliferation and polyploidization of Mk (Kaushansky, 2005; Rojnuckarin et al., 1999) 
(Figure 1.5).  
THPO and MPL are the most potent regulators of megakaryopoiesis (de Sauvage et al., 
1994). Thpo supports colony formation of megakaryocytes (Broudy et al., 1996; Majka et 
al., 2002). Antisense oligonucleotides against Mpl specifically inhibit megakaryopoiesis 
(Methia et al., 1993). The analysis of Mpl-/- mice (Alexander et al., 1996c) and Thpo-/- 
mice showed that these animals have a defective hematopoiesis with thrombocytopenia 
and drastically reduced numbers of HSC and progenitors (Carver-Moore et al., 1996; 
Murone et al., 1998). However, the maintenance of steady-state hematopoiesis is ensured 
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with only a few progenitor cells to populate and maintain the BM, spleen, and PB with 
nucleated cells in the mouse (Broxmeyer et al., 2005).  
 
 
 
Figure 1.5: Downstream signaling pathways of MPL (Kaushansky, 2005). Signaling pathways are activated by 
thrombopoietin binding to MPL. Several pathways for cell cycling processes are induced. Abbreviations: P 
phosphorylation, Y tyrosine residue, JAK2 Janus kinase 2, STAT3 and STAT5 Signal transducer and activator of 
transcription, Bcl-xL anti-apoptotic signaling molecule, SHC Src-homology collagen protein, Grb2 growth factor receptor 
bound protein 2, SOS son of sevenless, Ras rat sarcoma, Raf protein kinase, MAPK mitogen activated protein kinase, 
ERK1/2 extracellular signal-regulated kinase, PI3K phosphoinositol-3-kinase, SHP2 SH2 domain containing phosphatase-
2, Gab1 Grb2-associated binder, PIP2 membrane–bound phosphoinositol-4,5-biphosphate, PIP3 phosphoinositol-3,4,5-
triphosphate, Akt serine/threonine protein kinase, GSK3β glycogen synthase kinase-3, FOXO3a transcription factor, p27 
cell cycle inhibitor, SOCS suppressor of cytokine signaling. 
 
MPL is found on HSC and can be used as a selective surface marker on human HSC 
(Ninos et al., 2006). Mpl/Thpo support the proliferation and maturation of primitive 
hematopoietic progenitors and the HSC self-renewal (Ku et al., 1996; Sitnicka et al., 
1996; Tong et al., 2007). Mpl+/+/Thpo+/+ cells show a significantly better engraftment than 
Mpl-/-/Thpo+/+ cells in mice (Solar et al., 1998). Recent studies suggested that THPO 
signaling is also involved in the maintenance of HSC quiescence (Qian et al., 2007; 
Yoshihara et al., 2007). Mpl further is involved in the erythroid differentiation: Progeny 
of normal human burst-forming units-erythroid (BFU-E) contain Mpl receptor mRNA, 
and flow cytometric analysis shows the presence of Mpl receptor protein on the surface of 
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these cells (Broudy et al., 1997). Thpo was also found to expand erythroid progenitors, 
increase red cell production, and enhance erythroid recovery after myelosuppressive 
therapy (Kaushansky et al., 1995). The cross-reactivity of Thpo with the EpoR supports 
erythroid proliferation (Rouleau et al., 2004).  
Deregulation of either MPL or THPO is connected with several human disorders. 
Recently, a constitutively activating mutation of MPL (MplW515LK) was found which 
results in human myeloproliferative disorder (MPD) (Pardanani et al., 2006). Expression 
of MplW515LK in mouse BM induced an MPD-like disorder (Pikman et al., 2006). MPL 
Baltimore is an MPL receptor polymorphism associated with thrombocytosis at amino 
acid (aa) position K39N resulting in chronic myeloproliferative disorder (CMPD). 
Patients suffer from significantly higher platelet counts and show reduced MPL 
expression in platelets (Moliterno et al., 2004). Familial essential thrombocythemia (FET) 
is associated with a dominant-positive activating mutation of the MPL gene (Ding et al., 
2004). Absence of MPL is also discussed in negatively regulating the central nervous 
system (CNS) and the brain growth (Yang et al., 2004). A monogenous defect caused by 
mutations in the c-mpl gene is congenital amegakaryocytic thrombocytopenia (CAMT).   
 
1.5. CAMT is a hematopoietic disorder based on MPL inactivation  
Thrombocytopenias can be divided into inherited and acquired forms. Acquired 
thrombocytopenia results from infections, auto-immunity or medications. Inherited forms 
are very rare and often diagnosed in early childhood. Inherited thrombocytopenias are e.g. 
thrombocytopenia-radius-aplasia (TAR), wiskott-aldrich syndrome (WAS), fanconi 
anemia (FA) and congenital amegakaryocytic thrombocytopenia (CAMT).  
CAMT was first characterized 1974 as constitutively aplastic anemia type III (Hughes, 
1974). It is a very rare disease with about one to two new cases in Germany per year. 
CAMT is a recessive inherited BM failure syndrome starting with an isolated 
thrombocytopenia after birth in association with hypomegakaryocytic BM. Further 
progression of the disorder results in a pancytopenia affecting all hematopoietic lineages. 
The pancytopenia development points to a basic malfunction in hematopoiesis on the 
HSC level. Results of Freedman and Estrov showed that pancytopenia must originate 
from an intrinsic HSC defect (Freedman and Estrov, 1990). Patients suffer from 
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spontaneous bleeding which can become life-threatening and develop lethal aplastic 
anemia in the first years of their life. The only known therapy today is allogeneic BMT 
(Muraoka et al., 2005).  
Ihara et al. found point mutations in exons 4 and 10 of the c-mpl gene which led to a 
translational stop and therefore truncations of the MPL receptors (Ihara et al., 1999). In 
the following years, many nonsense and missense mutations were detected in the whole 
c-mpl gene, which directly correlates with the development of CAMT (Ballmaier et al., 
2001; Germeshausen et al., 2006; van den Oudenrijn et al., 2000) and aplastic anemia 
(Ballmaier et al., 2003). A genotype-phenotype correlation could be found which led to 
the identification of two CAMT subgroups, CAMT 1 and CAMT 2 (Germeshausen et al., 
2006). Mutations underlying CAMT 1 lead to a complete inactivity of the MPL receptor. 
These patients have low platelet counts directly after birth and develop pancytopenia in a 
short time. CAMT 2 patients have missense mutations which provide residual receptor 
activity. These patients show a moderate phenotype progression and develop 
pancytopenia in a later stage of life after about three years (Gandhi et al., 2005). New 
mutations are still found in MPL which cause CAMT (Passos-Coelho et al., 2007). 
Besides hematologic phenotypes resulting from MPL deficiency, malformations in other 
organs like heart and brains could be observed.  
 
1.6. Gene therapy is a possible treatment for CAMT  
The term gene therapy was created in the 1980s. Gene therapy describes the medical 
intervention by which genes are introduced into patient cells to cure a disease (Mulligan, 
1993). The approaches can be used to cure infectious diseases, to cure cancer and as a 
therapy for inherited disorders. The therapeutic strategy ranges from somatic gene 
therapy to germline therapy and from in vivo to ex vivo therapy. In somatic gene therapy, 
cells from patients are genetically altered to cure the disease but do not transmit the 
alterations to the offspring. With germline therapy, the alteration of the genome will also 
be transferred to the patient’s offspring which, is not desired and thus ethically banned in 
most countries. In vivo therapy entails the direct application of the therapeutic genes into 
the patient which is connected to many risks like nonspecific targeting of cells. The ex 
vivo approach is safer because cells from the patient are harvested and the therapeutic 
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gene is introduced into this defined population only. Afterwards, these cells are returned 
to the patient.  
The target for gene therapy in many hematopoietic disorders like CAMT are the HSC. 
The permanent introduction of a gene into an HSC means that all progeny cells arising 
from this cell carry the therapeutic gene which increases the chances for the therapy. HSC 
are harvested from patients and transduced with the recombinant gene vectors. The stem 
cell fraction has to be cultured or expanded ex vivo where the surface phenotype of the 
HSC changes from that of freshly isolated HSC. Depending on the cytokine cocktail used 
this does not necessarily alter their repopulation capability (Zhang and Lodish, 2005). 
The successful use of retroviral gene transfer has been shown in patients (Cavazzana-
Calvo et al., 2004). Recently, about 20 patients with X-linked severe combined 
immunodeficiency (SCID-X1) have been treated with HSC that were genetically 
modified with retroviral vectors, and most of the patients showed evidence of the 
therapeutic benefit of gene therapy (Cavazzana-Calvo et al., 2000; Kohn, 2008). 
Furthermore, correction of X-linked chronic granulomatous disease (CGD) by gene 
therapy could be shown (Ott et al., 2006). To mediate the addition of a therapeutic gene 
into the host genome, a transfer vehicle is needed (Mann et al., 1983). These transfer 
vehicles can be bacterial, non-viral (like naked DNA) or viral.  
 
1.7. Viral vectors for gene therapy  
Viral transfer constructs are called vectors and are based on different viruses depending 
on the application needed. Vectors can be non-integrating or integrating and introduce the 
therapeutic gene temporarily or permanently into the host cell. Retro- and lentiviral vector 
backbones like murine leukemia virus (MLV), human immunodeficiency virus (HIV) or 
foamy virus-based vectors integrate permanently into the host genome. For non-
integrating applications, adenoviral and adeno-associated viral vectors are very common 
(Flotte, 2007). Retroviral vectors have the advantage of providing efficient integration 
into the host genome with stable expression of the transgene in all progeny cells and the 
viral genes can be completely replaced by the recombinant transgene. A disadvantage for 
using retroviral vectors is their limited capacity for the therapeutic gene of about 8 kbp. 
Lentiviral vectors have the advantage of also infecting non-dividing cells compared to 
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retroviral vectors based on MLV (Baum et al., 2006; Vigna and Naldini, 2000). CAMT as 
a monogenous disorder resembles a classical target for a permanent somatic retroviral 
gene therapy of HSC.  
 
 
 
Figure 1.6: The gamma-retroviral particle (Galla, 2008). The scheme of a mature MLV (murine leukemia virus) 
retroviral particle shows several retroviral elements. Particles are surrounded by a membrane which includes the envelope 
surface proteins for binding to the host cell. The two RNA molecules are surrounded by the capsid. Several enzymes and 
accessory proteins are incorporated into the viral particle. Abbreviations: IN integrase, MA matrix, CA capsid, NC 
nucleocapsid, PR protease, RT reverse transcriptase, SU surface subunit, TM transmembrane subunit.  
 
Retroviral particles are about 100 nm in size and are surrounded by a membrane. This 
membrane incorporates the viral surface proteins (envelope, env). The membrane 
surrounds the core which is made of the gag protein (group specific antigen). Inside the 
core are more viral proteins like the viral protease (pro), the reverse transcriptase (RT) 
and the integrase. The genome is made up of two identical plus stranded RNA molecules 
(Coffin et al., 1996) (Figure 1.6). Retroviruses can infect defined cell populations by 
receptor-mediated fusion or endocytotic uptake (Greene and Peterlin, 2002). After 
binding to the host cell membrane (attachment) and entry, the capsid protein with the 
viral genome and further proteins are released (uncoating). Viral reverse transcriptase 
catalyses the transcription of the viral genomic RNA to viral DNA, after which the pre-
integration complex (PIC) is formed. The PIC may be transported into the nucleus. MLV 
lacks the ability to transduce non-dividing cells, therefore the nuclear membrane has to 
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break down during cell division. The viral integrase catalyses the process of DNA 
integration into the host genome. The viral DNA is transcribed and translated to build 
new virus particles and proteins. Viral RNA and proteins are transported to the host 
membrane and bud off the cell whereby the new virus is coated by the host membrane. 
Following maturation, new infectious virus particles are formed.  
 
 
 
Figure 1.7: Gene therapy with retroviral vectors (Baum et al., 2006). The vector particle binds with the env protein to 
specific surface markers of the target cell. Membranes of host and virus fuse and after capsid degradation the viral RNA 
and accessory proteins are brought into the cytoplasm. Reverse transcription takes place and the PIC (pre integration 
complex) is formed. The viral DNA and the integrase gain access to the nucleus after the nucleus membrane breaks down 
during mitosis. Viral DNA is then integrated into the host genome. The therapeutic gene can be transcribed and translated 
and can fulfill its function. Abbreviations: mRNA messenger RNA, ENV envelope protein, LTR long terminal repeat, 
RNAPII RNA polymerase II. 
 
The first retroviral vector was described in 1981 (Wei et al., 1981). This work was based 
on the harvey murine sarcoma virus and showed successful introduction of the thymidine 
kinase gene into thymidine kinase-/- cells. One year later, Tabin et al. reported the same 
experiment with the moloney murine leukemia virus (Tabin et al., 1982). Subsequently 
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positive selectable retroviral vectors containing the neoR gene for selection (Beck-Engeser 
et al., 1991; Friel et al., 1987; Ostertag et al., 1986) were built on the basis of the 
myeloproliferative sarcoma virus (Ostertag et al., 1980; Stocking et al., 1986) and other 
variants adapted to better expression in multipotent HSC (Grez et al., 1990).  
Gene therapy with retroviral vectors today mostly uses constructs based on gamma-
retroviruses (Miller and Rosman, 1989) and lentiviruses (Naldini, 1998). Common for all 
viral vectors is that gene therapy makes use of the normal replication process of viruses 
by which they introduce their genome into the host cell (Figure 1.7). An important safety 
feature of retroviral vectors is that they are replication-incompetent. This avoids the 
uncontrolled spread of gene therapy vectors in patients. The risk of horizontal gene 
transfer (to other persons) or vertical gene transfer (to the patient’s offspring) is thereby 
eliminated. The transcription and translation of the vector coding genes do not produce 
proteins to build new viruses but translate the therapeutic gene.  
 
 
 
Figure 1.8: Viral vectors and packaging plasmids. Plasmids are used to produce retroviral particles for gene therapy 
harboring the gene of interest. For safety reasons proteins like integrase (IN), reverse transcriptase (RT), protease (PR) 
(gag-pol) and envelope proteins (env) are separated on different plasmids. Additionally the packaging signals (Ψ) on these 
constructs are removed, to avoid the packaging of the viral protein coding sequences into the new viral particles. Only the 
retroviral vector harboring the gene of interest has the packaging signal. Via co-transfection of those vectors (gag-pol, env) 
replication defective viral particles are produced. Abbreviations: AmpR ampicillin resistance, ori origin of replication, MP 
murine leukemia virus promoter, SD splice donor, SA splice acceptor, wPRE woodchuck hepatitis virus posttranscriptional 
regulatory element, SF spleen focus forming virus promoter, SV40 simian virus 40, gag/pol accessory proteins, env 
envelope, eco ecotroph, pA poly A signal, Ef1α Ef1α  promoter, Ires internal ribosome entry site, puro puromycin. 
 
 
 
 
 
Introduction   
29 
29
The reason for vectors being replication-incompetent is based on the deletion of 
important viral genes like the gag, pro, pol and env genes. This is possible because the 
early steps of replication of a retrovirus (attachment, reverse transcription, integration, 
synthesis) are not dependent on the coding sequences of the vector. The elimination of the 
retroviral genes provides space for the therapeutic sequences (Mulligan, 1993). The gene 
of interest is thereby flanked with viral long terminal repeats (LTR). These are strong 
enhancer-promoter regions which provide high transgene expression (Figure 1.8).  
The LTR U3 (unique 3) region (500 bp) provides the enhancer-promoter activity, the R 
region (60 bp) forms the cap and polyadenylation site of the LTR and the U5 region (75 
bp) is essential for the reverse transcription and integration. Vectors are not able to 
produce new vector particles until viral regulatory enzymes and proteins are co-
transfected. For safety reasons, these proteins are encoded on other plasmids lacking the 
packaging signal (Ψ) (Berkowitz et al., 1996). Gag with all of its components (matrix, 
capsid, nucleocapsid) provides the viral enzymes like the reverse transcriptase (RT), 
integrase (IN) and protease (PR) (Figure 1.8). Eco (ecotropic = mouse cells) encodes the 
envelope env-protein recognizing the murine ecotropic mCAT-1 receptor (Wang et al., 
1991). Also, the use of packaging cell lines instead of co-transfection is very common 
(Markowitz et al., 1988a; Markowitz et al., 1988b). After the co-transfection or 
transfection of a packaging cell line, viral particles are produced similar to normal 
retroviral infection. But only the therapeutic vector harboring the packaging signal (Ψ) is 
packaged into the viral particles. They bud off the membrane and secrete into the 
surrounding media. After sterile filtrating the media supernatant, which also removes 
cells and cell debris, it can be used to transduce target cells.  
 
1.8. Gene therapy bears the risk of side effects  
Gene therapy with retroviral vectors uses the ability of viruses to introduce their viral 
genome permanently into the host genome. This mechanism bears the risk of insertional 
mutagenesis and toxicity of the transgene (Baum et al., 2003). The introduction of the 
viral DNA into the host genome is more or less random with preferences depending on 
the vector type (Laufs et al., 2003; Schroder et al., 2002; Wu et al., 2003). Viral DNA can 
insert into the coding region of a gene (exon insertion) in HSC and thereby destroy the 
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gene, which can have severe consequences for hematopoiesis. Furthermore, viral vectors 
can insert into the non-coding region of a gene (intron insertion) which can influence the 
splicing. However, the most common integration site found after natural selection for 
gamma-retroviruses are in front of a gene in the 5’ untranslated or promoter region (Wu 
et al., 2003) or in other DNAse I hypersensitive sites that may overlap with regulatory 
regions (Lewinski et al., 2006). These integrations can influence the expression pattern 
via promoter interference or enhancer interactions. Vectors contain strong enhancer and 
promoter elements to ensure a good expression level of the transgene. However, the 
enhancer-promoter activity can also target neighboring host genes which can strongly 
deregulate their gene expression. Overexpression of proto-oncogenes can lead to an 
increased signaling or suppressed apoptosis, resulting in uncontrolled proliferation and 
dysplasia. With or without further additional insertions, the cell can became 
leukemogenic after gene therapy (Hacein-Bey-Abina et al., 2003; Li et al., 2002; Modlich 
et al., 2005) (Figure 1.9). 
 
 
 
Figure 1.9: Side effects of retroviral insertion. Viral vectors integrate randomly into the host genome. Enhancer-
promoter regions (LTR) of the vectors drive the transgene expression. The LTRs also induce activation of host genes in 
close proximity. This can lead to genotoxicity via insertional mutagenesis. Abbreviations: LTR long terminal repeat. 
 
Another risk for mutations in gene therapy with retroviral vectors is found in the process 
of reverse transcription of the viral RNA. Point mutations or the sequence rearrangements 
and recombination of the viral genome are an evolutionary advantage for the virus but 
bear the risk of side effects in gene therapy. Following the transduction, the viral RNA is 
transcribed into a copy of viral DNA. The reverse transcriptase has no proofreading 
activity which can lead to point mutations. On average, RT introduces mistakes into 1 of 
every 104 to 105 base pairs (Mansky, 1998). For transgenes like cytokine receptors (such 
as MPL) this can be a risk because single point mutations and endangered regions are 
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known which can lead to constitutive activation of the receptor (Abe et al., 2002; 
Pardanani et al., 2006; Romanelli et al., 2006). These activating mutations can have 
similar consequences like the upregulation of genes via insertional mutagenesis. Aberrant 
signaling and the increase of downstream targets of the receptor can lead to 
immortalization and increased proliferation. However the risk of acquiring one of these 
activating mutations is statistically very low. 
 
1.9. Safer vector constructs and transgene design can reduce side effects  
Major research is ongoing to develop methods to reduce genotoxic side effects of gene 
therapy (Baum et al., 2006). One way is to design safer vector constructs by deleting the 
strong enhancer-promoter regions of the early generations of gamma-retroviral vectors. 
These vectors are called self inactivating vectors (SIN) (Schambach et al., 2006b; Yu et 
al., 1986) (Figure 1.10).  
Following the deletion of the U3 region, an internal promoter (IP) is needed to drive 
transgene expression. It is thus possible to use promoters that show a more physiological 
transgene regulation and avoid the activation of surrounding host genes (Zychlinski et al., 
2008). However, these promoters still need to produce high enough amounts of transgene 
product to reach therapeutically relevant levels (Schambach et al., 2006a).  
 
 
 
Figure 1.10: Self inactivating vector design. A standard retroviral vector (SF91) is flanked by the two LTR regions which 
are strong enhancer-promoter elements. After integration into the host genome the LTRs can induce transcription of 
surrounding genes and lead to insertional mutagenesis. To reduce the risk of side effects after gene therapy the enhancer-
promoter activity of the LTRs is deleted from the U3 region. These vectors are called self inactivating (SIN) vectors. Now 
an internal promoter is needed for transgene expression. Abbreviations: SF spleen focus forming virus enhancer-promoter, 
SD splice donor, SA splice acceptor, Ψ packaging signal, wPRE woodchuck hepatitis virus posttranscriptional regulatory 
element, IP internal promoter. 
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Furthermore, promoters can be differentiation-specific (endogenous promoters) and 
mediate expression only in the specific tissue compartment. There are several more 
strategies for reducing side effects, like insulators, included sequences in the viral LTR, 
which reduce host gene activation from the internal promoter by shielding (Emery et al., 
2000). Furthermore small molecular RNA target sequences (Brown et al., 2007) can be 
introduced into the vectors to restrict RNA translation in non-target cells.  
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1.10. Specific aims of this work 
 
CAMT is an inherited BM failure syndrome resulting from inactivating mutations in the 
THPO receptor MPL. The only known therapy today is allogeneic BMT. In an 
experimental approach, we wanted to develop a curative gene therapy for CAMT. A gene 
therapy would be of great benefit for CAMT patients because it is very difficult to find a 
matching donor for allogeneic BMT and it still bears the risk of the rejection of the donor 
cells. 
 
With our approach we wished to answer the following questions:  
What is the consequence of ectopic Mpl expression? 
What are the mechanisms of hematopoietic alterations caused by ectopic Mpl expression? 
Can we define a therapeutic index for CAMT gene therapy? 
 
Earlier, some groups described the expression of Mpl in vitro and in vivo. In most cases, 
the mechanisms for effects resulting from overexpression of Mpl could not be found or 
originated from the expression system, like the use of replicative competent virus. We 
wanted to address the above questions in our experimental setup by retrovirally 
overexpressing murine Mpl on HSC after BMT into lethally irradiated mice. CAMT 
patients need a lifelong expression of the therapeutic gene. To ensure this criterion, we 
decided to choose a gamma-retroviral vector system which permanently integrates into 
the host genome. Retroviruses bear the risk of malignant clonal dominance by insertional 
mutagenesis. Following that, we wanted to perform a broad risk management addressing 
the insertion sites and the ectopic overexpression. In vitro experiments should be 
performed to ensure the function of the transgene and vector and gain a first prediction 
for the in vivo experiments. Mice should be analyzed macroscopically, 
histopathologically and molecularly to clarify the mechanisms causing possible side 
effects. We also wanted to design safer and better vectors based on the results of the 
previous experiments to gain a therapeutic expression of Mpl.   
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2. Materials & Methods 
 
2.1. Molecular biological techniques 
 
If not stated otherwise, standard protocols by E.F. Fritsch, J. Sambrook, and T. Maniatis 
(1989) were used. 
 
Bacteria 
DH5α and XL1-Blue were used for transformation of plasmid DNA. These bacteria are 
derived from Escherichia coli K12. For cultivation of bacteria, LB (Becton Dickinson, 
Heidelberg, Germany) media including Ampicillin (final concentration 100 µg/mL) were 
used.  
 
Retroviral vectors and DNA work 
For transgene expression in vitro and in vivo, an LTR-driven gamma-retroviral vector 
(SF91) containing the spleen focus-forming virus (SF) enhancer-promoter element 
(Hildinger et al., 1999; Schambach et al., 2000) and gamma-retroviral self-inactivating 
vector constructs (SIN), which have a deletion in the U3 region to remove the enhancer-
promoter elements were used (Schambach et al., 2006b). Because cloning of the vectors 
was a major part of this work, transgenes, their modifications and the vector constructs 
are described in “Results”. Plasmid DNA isolation and purification methods are based on 
alkaline lysis (Birnboim and Doly, 1979). Depending on the amount of plasmid DNA, the 
QIAprep Miniprep Kit or Qiagen Plasmid Purification Maxi Kit (Qiagen GmbH, Hilden, 
Germany) was used following the manufacturer’s instructions. When purification by 
phenol extraction and ethanol precipitation was performed, the protocol of (Chomczynski 
and Sacchi, 1987) was used. Enzymatic digestion of plasmid was performed with 
nucleases from Fermentas GmbH, St. Leon-Rot, Germany, following the manufacturer’s 
instructions. DNA fragments were electrophoretically analyzed in a 1.0 to 1.2% agarose 
gel (Seakem LE Agarose, Lonza Group Ltd, Basel, Switzerland) and DNA was cut out of 
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the gel and purified with the QIAquick Gel Extraction Kit (Qiagen). Phosphorylation 
with T4 polynucleotide kinase of PCR products or dephosphorylation with calf intestine 
alkaline phosphatase of vector backbones was carried out with enzymes from Fermentas. 
Ligation of DNA fragments was performed with ligase (Fermentas) and transformation of 
ligated constructs into competent DH5α or XL1-Blue was done following standard 
protocols.  
 
Table 2.1: Primer for Mpl mutants 
# Oligo Function
1 TTG GGC GTA GTC GGG CAC GTC GTA GGG GTA TTG GCT GGT GAC TTG TGC CTG GTT TGG HA-tag
2 GAG GTC TGC AGT GGA AGG CTG GAG caMpl
3 GGA GAT GCA GTG ACA ATT GGA CTT CAG ntMpl-fw
4 TTG GGC GTA GTC GGG CAC GTC G ntMpl-rev
5 GGA ATT CTC ACA GAG GGA AAG GAG TGC TCT CTG nrMpl  
 
Preparation of Genomic DNA 
DNA of peripheral blood leukocytes, BM or spleen was purified using QIAmp Blood 
DNA Preparation Kit (Qiagen) following the manufacturer’s instructions. Briefly, cells 
were lysed with Qiagen lysis buffer and protease K at 56°C for 10 min. Suspension was 
precipitated with Qiagen buffer and genomic DNA was purified with separation columns. 
The concentration of genomic DNA was determined in a photometer and DNA was 
stored at 4°C until use. 
 
Preparation of RNA 
BM cells were washed with PBS and pellet was lysed after centrifugation in 1 mL 
RNAzole (WAK Chemie GmbH, Steinbach, Germany). 200 µL chloroform was added to 
the suspension, vortexed and centrifuged afterwards for 15 min at 4°C. The hydrophilic 
part was collected and precipitated with isopropanol (16,000 g, 30 min, 4°C). Pellet was 
washed with 75% EtOH and resuspended in water including RNAase inhibitors 
(Fermentas) and stored at -20°C.  
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qPCR (quantitative PCR) 
For quantification of vector copy numbers from BM, spleen or PB, genomic DNA was 
used with a primer detecting a 94 bp wPRE-specific sequence (wPRE-specific primers 
forward 5’-GAG GAG TTG TGG CCC GTT GT-3’ and reverse 5’-TGA CAG GTG 
GTG GCA ATG CC-3’). The wPRE signal was normalized by the signal of a 
housekeeping gene flk-1 intron enhancer (AF061804, bases 352-459, forward 5'-GTG 
AAT TGC AGA GCT GTG TGT TG-3' and reverse 5'-ATT CAT TGT ATA AAG GTG 
GGA TTG-3') using the Sybr Green (Qiagen) reagent on a 7300 Real Time PCR System 
(Applied Biosystems, Foster City, USA). Results were quantified using the comparative 
CT method.  
Titer of the SIN.MplP.wtMpl expressing SC1 cells was alternatively determined to flow 
cytometry via qPCR. CT values for MplP-driven constructs were compared to the SF 
promoter-driven constructs as detected by flow cytometry for titer determination. 
 
Reverse Transcriptase PCR and Real Time PCR 
RNA from BM cells was reverse transcribed with the Qiagen QuantiTect Kit following 
the manufacturer’s instructions (Qiagen). Briefly, RNA, reverse transcriptase, oligo 
nucleotides and Qiagen buffer were mixed in appropriate amounts and incubated 30 min 
at 37°C. cDNA content was measured on a photometer. cDNA was then used for real 
time PCR (7300 Real Time PCR System, Applied Biosystems) which was performed 
after the following cycling protocol for Sybr Green (Qiagen): 95°C 15 min; 40x: 60°C 0.5 
min, 72°C 0.5 min, 95°C 0.25 min; 60°C 0.5 min, 95°C 0.25 min. Primers for the Mpl 
sequence were used from Qiagen. Results were quantified using the comparative CT 
method. 
 
LM-PCR (Ligation-Mediated PCR) 
LM-PCR was performed as described previously (Schmidt et al., 2001). Briefly, 100 ng – 
500 ng DNA were digested with 2.5 U Tsp509I (New England BioLabs GmbH, 
Frankfurt, Germany). Primer extension was performed following the first PCR (95°C 5 
min; 30x: 95°C 1 min, 55°C 0.5 min, 68°C 2 min; 68°C 10 min) using Extensor Hi-
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Fidelity PCR Master Mix (ABgene, Hamburg, Germany). The nested PCR was 
performed under identical conditions. PCR products were isolated by gel electrophoresis, 
purified using QIA Quick Gel Extraction Kit (Qiagen) and sequenced (Beckman Coulter 
GmbH, Krefeld, Germany) after subcloning into TA cloning vector (Invitrogen GmbH, 
Karlsruhe, Germany). Recovered sequences were screened using the NCBI mouse 
genome database (NCBI37, accessed April 2008).  
 
Sequencing 
Sequencing was performed with the DTCS Quick Start Kit on the Beckman Coulter CEQ 
8000 sequencer following the manufacturer’s instructions (Beckman Coulter). Briefly, 
DNA was incubated with appropriate primers, polymerase and fluorescent labeled oligo-
nucleotides provided in a master mix by Beckman Coulter. Sequencing reaction was done 
under following conditions: 96°C 1 min, 50°C 20 sec, 60°C 4 min 33 cycles. DNA was 
precipitated with isopropanol (17,000 g, 30 min, 4°C) and pellet dissolved in the 
manufacturer’s buffer. Mix was then sequenced and analyzed with CEQ Systems 
software and DNAStar.  
 
Table 2.2: Primer for Mpl cDNA sequencing 
# Oligo Function
1 ATG CCC TCT TGG GCC CTC TTC ATG sequencing
2 GAG GAC CTC ACC TGC TTC TGG sequencing
3 GCT GGA TCA AAG TCT GGT TGA G sequencing
4 GAA ACC TGC TGC CCC ACT TTG sequencing
5 GAA CCG CGT CCA GGGA TCA CAG sequencing
6 GTG ACT GCT CTG CTC CTG GTG sequencing  
 
Table 2.3: Primer for MplP (promoter) cDNA sequencing 
# Oligo Function
1 GAA GCT TGC TTG TAG AAC AGG CTG sequencing
2 GCT TCC ACC TTC TGT GAG CTG sequencing
3 GAG GTT AGA GGG CAT TTA AAG sequencing
4 GTC CAG GAC AGC TAG GAG GAG sequencing
5 GAG CAC ACA CCA AGG TTG CTG sequencing
6 GTG TCT CCA TTT GAT TCA CAG sequencing
7 CTT CTC CGG CAC TGT GTG CCT GCC TTA G sequencing  
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Southern Blots 
10 µg of genomic DNA from wPRE transgenic cells was digested with BglII or NheI 
(Fermentas) and electrophoretically (0.8% agarose gel, 24 V, over night) separated. DNA 
was blotted on a nitro cellulose membrane (PALL Corporation, Pensacola, USA) by 
diffusion. DNA was fixed by heat at 80°C for 2 h and hybridized with the 700 bp 32P 
αdCTP radioactively labeled probe for the wPRE. In the case of SF91.RRE.caMpl vectors 
which do not inherit the wPRE element, the probe was generated from the RRE element 
by digestion with SpeI and NotI (Fermentas). 
 
Preparation of Protein Lysates 
32D cells were transduced with viral supernatant and cells were grown to reasonable 
numbers. Cells were starved overnight in minimal media (RPMI, 4% BSA) and 
stimulated on the following day with different cytokines (Thpo, IL-3) for 10 min 
(PeproTech GmbH, Hamburg, Germany). Cells were then washed in ice-cold PBS with 
phosphatase inhibitors (sodium orthovanadate) and pelleted (17,000 g, 10 min, 4°C). 
Afterwards pellet was applied to lysis buffer (50 mM HEPES, 150 mM NaCl, 50 mM 
NaF, 10 mM Na4P2O7, 10% glycerin, 1% IGPAL) including phosphatase and protein 
inhibitors (leupeptin, pepstatin, EDTA, phenylmethylsulfonyl fluoride [PMSF], 
pefablock, aprotinin) and frozen to -80°C (Meyer et al., 1998). To determine the protein 
concentration, lysates were diluted and mixed with the Bradford reagent (BioRad 
Laboratories GmbH, München, Germany). Suspension was applied to a photometer 
measuring at 595 nm and concentration of proteins calculated compared to standard 
controls (dilution serious of BSA).  
 
Western Blots 
10 - 20 µg of protein samples were separated by electrophoresis as described previously 
(Meyer et al., 1998). Briefly, protein lysates were loaded on a 5% collection acryl amid 
gel and 9% separation acryl amid gel, 1 – 2 h at 40 mA in running buffer (0.1% SDS, 15 
µg/mL glycine, 3 µg/mL Tris). Blotting was performed (1 - 2 h, 300 – 400 mA, 4°C, 
transfer buffer: 1% SDS, 20% methanol) on a nitrocellulose membrane (PALL 
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Corporation) which was afterwards blocked in 5% milk (Carl Roth, Karlsruhe, Germany) 
and incubated with one of the following antibodies: anti-pERK (p44/42 MAPK, 
T202/Y204) and anti-pAKT (Ser473). For loading controls, blots were stripped and 
reprobed using anti-ERK and anti-AKT antibodies (Cell Signaling Technology, Danvers, 
USA). Appropriate secondary antibodies were used coupled to horseradish peroxidase 
(Santa Cruz Biotechnology, Heidelberg, Germany) using SuperSignal West Pico 
Chemiluminescent Substrate (Pierce Biotechnology, Rockford, USA).  
 
EMSA (Electromobility Shift Assay) 
EMSA and Supershift were performed to detect STAT3 and STAT5 activation (Meyer et 
al., 2002). The same protein lysates were used as for Western blots. Briefly, DNA 
substrate β-casein for STAT5 and USTE-oligo for STAT3 were P32 γ-ATP radioactively 
labeled and incubated (30 min, RT) with the protein lysates (1 - 2 µg). Afterwards, 
DNA/protein mixture was separated by electrophoresis (20% acryl amid gel, 2 - 3 h, 300 
volt) and analyzed by autoradiography. For Supershift protein/DNA mixture was 
incubated additionally 30 min with STAT-specific antibodies c-terminal anti-STAT3 (C-
20), n-terminal anti-STAT5N (N-20) or c-terminal anti-STAT5C (C-17) (Santa Cruz 
Biotechnology) following the same separation by electrophoresis. 
 
Thpo ELISA 
Plasma was collected from peripheral blood samples by centrifugation 10 min at 400 g. 
Supernatant was collected and frozen at -20 °C. Thpo ELISA on 96-well plates was 
performed following the manufacturer’s protocols (Quantikine M, R&D Systems GmbH, 
Wiesbaden-Nordenstadt, Germany) using precoated 96-well antibody plates.      
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2.2. Cell culture techniques and analysis 
 
Cells and Cell Lines 
All cells were cultivated in an incubator (Heraeus Holding GmbH, Hanau, Germany) at 
37 °C, 5% CO2 and H2O saturated air. 
SC1 is an adherently growing fibroblast cell line obtained from a mouse embryo. Cells 
are susceptible to murine leukemia virus (MLV) and were cultivated in DMEM (PAA 
Laboratories GmbH, Cölbe, Germany, 10% FCS, 100 µg/mL penicillin and 50 µg/mL 
streptavidin, 1% L-glutamine) (Hartley and Rowe, 1975).  
293T is an adherently growing epithelial cell line derived from human kidney. 293T is a 
highly transfectable derivative of the 293 cell line into which the temperature-sensitive 
gene for SV40 T-antigen was inserted (Pear et al., 1993). Cultivation was performed in 
DMEM media (PAA Laboratories, 10% FCS, 100 µg/mL penicillin and 50 µg/mL 
streptavidin, 1% L-glutamine). 
32D mouse BM cell line was established from long-term BM cultures of C3H/HeJ mice 
infected with the friend murine leukemia virus and are constitutively growth factor-
dependent (Greenberger et al., 1983). Cells were cultivated in RPMI media (PAA 
Laboratories) containing 10 ng/mL IL-3, 10% FCS, 100 µg/mL penicillin, 50 µg/mL 
streptavidin and 1% L-glutamine. 
BM Lin- (WT, KO) were derived from freshly sacrificed animals. Bones were flushed or 
crushed depending on the application and mononuclear cells were enriched via 
histopaque (Sigma-Aldrich, St. Louis, USA) gradient separation or directly used for 
MACS (magnetic associated cell sorting) separation. Cells were incubated with lineage-
depleting antibodies and beads (MACS Lineage Cell Depletion Kit, Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany). The cell suspension was then separated via 
MACS and lineage-negative cells were frozen alive (10% DMSO, 90% FCS) or 
cultivated in StemSpan media (StemCell Technologies, Grenoble, France) with 100 
µg/mL penicillin, 50 µg/mL streptavidin, 1% L-glutamine and cytokines (10 ng/mL IL-3, 
25 ng/mL SCF, 100 ng/mL IL-11, 100 ng/mL Flt-3L, PeproTech).   
Spleen cells were singularized by pressing the spleen through a cell strainer (70 µm, 
Sarstedt GmbH, Sartstedt, Germany). Afterwards cells were frozen alive (10% DMSO, 
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90% FCS) or kept in StemSpan media (StemCell Technologies) with 100 µg/mL 
penicillin, 50 µg/mL streptavidin, 1% L-glutamine and cytokines (IL-3, SCF, IL-11, Flt-
3L, PeproTech).   
 
Virus Production (transfection) 
293T cells were plated one day before transfection in a concentration of 5 x 106 cells in a 
10 cm culture dish in 10 mL media. On the following day, co-transfection of the 
transgene-expressing vector with viral-gag-pol (M57-DAW) and viral-env (K73eco)-
expressing vectors (Figure 1.8) using the calciumphosphat (Ca3(PO4)2) transfection 
method was performed. Supernatant was harvested 36 h, 48 h, 60 h and 72 h post-
transfection, sterile filtered (70 µm) and frozen at -20°C. An aliquot was taken for 
estimation of the viral titer. 
 
Virus Titration (transduction) 
SC1 cells were plated one day before transduction in a concentration of 1 x 105 cells/mL 
in a 24-well plate. On the following day, cells were transduced with the virus supernatant 
with different amounts (1 µL, 5 µL and 20 µL). Titer was measured two days afterwards 
by flow cytometry and was determined using the following formula: 
 
( )
volumevirus
numbercellcellspostiter ⋅= .   
 
Growth Kinetic Assays (32D) 
32D cells were transduced with different vector constructs expressing either wtMpl, 
mutated receptor forms (caMpl, RRE.caMpl, ntMpl, nrMpl, cnnMpl) or fluorescence 
control proteins (GFP) and cultivated in different cytokine conditions (IL-3, Thpo, w/o). 
Growth was measured up to 14 d and cultures were splitted when necessary. Transgene 
expression was regularly checked by flow cytometry. Surviving cells were harvested for 
final analysis by flow cytometry.  
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Megakaryocyte Differentiation Assay 
Lin- BM cells were harvested from C57Bl6/J mice WT or Mpl-/- and transduced by the 
retronectin method with Mpl-expressing vector constructs or GFP as a control. One day 
after transduction cells were switched to media supporting megakaryocyte growth 
including StemSpan (StemCell Technologies), 100 µg/mL penicillin, 50 µg/mL 
streptavidin, 1% L-glutamine (PAA Laboratories), 25 ng/mL SCF, 100 ng/mL IL-6, and 
50 ng/mL Thpo (PeproTech). Cells were further expanded in this media for 12 to 14 d 
and cytospins were generated by centrifugation 100 g for 8 min for microscopic analysis. 
Megakaryocytes were counted after May-Grünwald/ Giemsa staining.  
 
Colony-Forming Assays (CFU) 
Myeloid colony–forming assays were performed in methyl cellulose-based medium 
(M3434) containing 3 U/mL erythropoietin, 10 ng/mL IL-3, 10 ng/mL IL-6, and 50 
ng/mL SCF (full media), and in M3234 medium containing 50 ng/mL murine Thpo w/o 
additional cytokines (Thpo media), as per the manufacturer’s protocols (StemCell 
Technologies). Cells were plated at 2.5 x 105 cells per dish for BM cells and 2.5 x 104 
cells per dish for Lin- BM cells, in duplicates. Plates were incubated at 37 °C for 7 d and 
colonies were counted.  
 
Spectral Karyotype (SKY) Analysis 
Leukemogenic cells from singularized spleen cells were cultivated two to four days in 
StemSpan media. Cells were then incubated with colcemid for 5 h and metaphase-
chromosomes were prepared. The samples were dehydrated in 22°C and 48% H2O 
saturated air in an increasing ethanol gradient and dried over night at 37°C. Hybridization 
was done with SKY-Paint-Kit DNA-M10 (Applied Spectral Imaging, Migdal HaEmek, 
Israel) for 2 d.  After counterstaining with DAPI, samples were analyzed using a 
fluorescence microscope. 10 - 15 metaphases were analyzed per sample. 
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2.3. Mouse experiments and analysis 
 
Animals (C57Bl6/J, CD45.1 (Ly5.1), WT and Mpl KO) 
C57Bl6/J mice were obtained from The Jackson Laboratory (Bar Harbor, Maine, USA). 
All mice were bred and kept in the pathogen-free animal facilities of the Hannover 
Medical School, Germany. Ly5.1 and Mpl KO animals were derived for our own 
breeding. Animal experiments were approved by the local ethics committee and 
performed according to their guidelines. 
 
Murine Bone Marrow Transplantation Model (BMT)  
Lin- BM cells of C57Bl6/J mice were transduced and transplanted as previously 
described (Li et al., 2003; Modlich et al., 2005). Briefly, Lin- cell population was cultured 
for two days in StemSpan media (StemCell Technologies), containing 25 ng/mL SCF, 
100 ng/mL Flt-3L, 100 ng/mL IL-11, 10 ng/mL IL-3, 100 µg/mL penicillin, 50 µg/mL 
streptavidin and 2 mM L-glutamine. Lin- cells were infected on two following days (day 
3 and 4) using Retronectin-coated plates (TaKaRa, Otsu, Japan) and vector. For 
preparation of plates, the surface of the wells was coated with 24 ng/mL Retronectin and 
virus-loaded by centrifugation of viral supernatants at 900 - 1000 g for 30 minutes at 4°C. 
Virus preloading was repeated up to two times. Transgene expression was measured on 
day 5 just prior to transplantation. 5 - 10 x 105 cells were transplanted into lethally 
irradiated mice (gamma irradiation, 0.45 Gy/min, 6MV Photons).   
 
Mouse Analysis 
Mice were sacrificed for final analysis or when they were moribund and showed clear 
symptomatic and macroscopically pathological abnormalities. Enlarged organs were 
weighed. A panel of tissues (spleen, kidney, liver, heart, lung, sternum) was collected, 
fixed in 4% formalin, and paraffin-embedded for histological examination. Cells from 
BM, spleen and PB were subjected to flow cytometry (FACS). Blood was collected from 
the armpit and analyzed by cell counter (Scil ABC Vet Blood Counter, ABX Diagnostics, 
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Montpellier, France) and blood smears. Plasma was purified by centrifugation 400 g for 
10 min and platelets and Thpo levels were analyzed. Genomic DNA was used for copy 
number determination, LM-PCR and Southern blot analysis. 
 
Flow Cytometry (FACS Calibur, Aria) 
Cells from BM, spleen and PB were subjected to flow cytometry (Becton Dickinson) and 
analyzed with CellQuest and Diva software (BD Biosciences, Heidelberg, Germany). 
After RBC lysis, PB cells were stained with lineage-specific antibodies against Gr1, 
CD11b, TER119, CD71, CD19, CD3, Sca1, ckit, lineage marker cocktail, CD34, 
CD16/32 or HA-Tag (Becton Dickinson; eBioscience, San Diego, USA; Roche 
Diagnostics, Mannheim, Germany). Antibodies were usually linked to FITC, PE, APC, 
Alexa488, Alexa700, PerCP-Cy5.5, PE-Cy7 fluorochromes or a secondary antibody via 
biotin-streptavidin binding was used. Dead cells were excluded by propidium iodide (PI) 
or 4', 6-diamidino-2- phenylindole dihydrochloride (DAPI) staining. 
 
Blood Samples and Marking of Animals 
Peripheral blood was collected periodically from the retro-orbital cavity using EDTA-
treated glass capillary tubes (BD Bioscience) or by final analysis after narcotization with 
diethyl ether from the armpit. RBC lysis was performed from PB when using for flow 
cytometry (RBC lysis buffer: 10 mM KHCO3, 0.15 mM NH4Cl, 0.1 mM Na2EDTA, 
pH7.3). Samples were analyzed by automated complete differential blood cell counts 
(Scil ABC Vet Blood Counter, ABX Diagnostics). Blood smears were performed and 
leukocyte morphology was evaluated by May-Grünwald/Giemsa staining. For further 
analysis, genomic DNA was prepared from PB. After centrifugation 10 min by 400 g 
plasma was purified from blood samples and platelets were analyzed by flow cytometry 
and Thpo level was measured by ELISA. Animals were marked with ear clip tongs. 
 
Cytospins 
Cells from spleen or BM were singularized and 1 to 2 x 105 cells in 200 µL PBS were 
spun (10 min, 150 g) on glass slides. Leukocyte morphology was evaluated by May-
Grünwald/Giemsa staining and cytospins were fixed with fixation and a cover glass.  
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Histopathology 
Organs of mice (sternum, spleen, liver, kidney, heart, and lung) were taken for histology. 
Bones were decalcified and organs were trimmed for paraffin embedding. All necropsies 
were fixed in buffered methanol-formol (BM) or formalin solution (specimens from the 
other organs) for at least 24 hours and embedded in paraffin (WAX) after decalcification 
of the BM specimens by ethylenediaminetetraacetic acid. From all necropsies, 3 µm thick 
sections were cut and stained with hematoxylin-eosin (HE), Giemsa, PAS (Periodic Acid 
Schiff), Prussian blue and Gomori silver impregnation. Micrographs were taken with an 
Olympus Microscope BX51TF (Olympus, Japan). 
 
Statistical Analysis 
Student’s T-Test: With independent groups of observation one is interested in the mean 
difference between two groups, but the variability between subjects becomes important. 
Both the confidence interval and the two sample t tests are based on the assumption that 
each set of observations is sampled from a population with a Normal distribution, and 
that the variances of the two populations are the same. So the t test with unequal 
variations (which means that we do not have information requiring us to assume equal 
variation) and two tailed (which means that the mean can be higher or lower as the 
control group) is an appropriate method (Altman, 1999). 
Wilcoxon Signed Rank Test: is a non-parametric test for 2 continuous variables. It is 
similar to the Student's T-test in that it also is a test for 2 continuous variables, but unlike 
the t-test the Wilcoxon signed rank test (also named Mann-Whitney U test) it does not 
require assumptions about normality of the distribution. It can therefore be used on data 
that is not normally distributed (Altman, 1999).  
Log Rank Test: Survival data is usually tested with a log rank test. The log rank test is a 
non-parametric method for testing the null hypothesis that the groups being compared are 
samples from the same population as regards to survival experience (Altman, 1999). 
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3. Results 
 
 
3.1.                                                                      
Murine bone marrow transplantation reveals the narrow 
therapeutic window for CAMT gene therapy 
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3.1.1. Mpl receptor and vector construction 
The c-mpl cDNA contains the signal peptide (SP), the extracellular domain (ECD), the 
transmembrane domain (TMD) and the intracellular domain (ICD) (Figure 3.1A). The SP 
is cleaved off by proteases after processing to the cell membrane. To detect the receptor 
via antibodies by flow cytometry and to distinguish it from endogenous Mpl receptor 
molecules, a hemagglutinine tag (HA-tag) was added to Mpl at position bp 78 between 
the SP and the ECD via PCR (Figure 3.1A, Appendix 6.2). HA is a nine-amino-acid-long 
peptide which is recognized by specific monoclonal antibodies (mAb). The mAb are 
coupled to fluochromes like FITC or specific binding sites like biotin for secondary mAb. 
The complete cDNA containing the HA-tag was introduced into the pcDNA3.1 cloning 
vector backbone from Invitrogen via NotI and BamHI restriction sites (Figure 3.1B). The 
expressing plasmid was used for transfection of 293T cells by the calcium phosphate 
method. Two days after transfection, transgene-positive cells could be detected by flow 
cytometry analysis after HA-tag-FITC mAb staining (Figure 3.1C). The HA-tagged Mpl 
construct was then introduced via NotI and EcoRI into the viral gamma-retroviral vector 
backbone based on the murine leukemia virus (MLV) (Figure 3.2A). The LTR-driven 
vector (SF91) contained the spleen focus-forming virus (SF) enhancer-promoter element 
and the MESV-derived gag-frame leader 91 (Hildinger et al., 1999; Schambach et al., 
2000). Viral supernatants were produced by transfecting 293T cells with the LTR driven 
vectors. 32D cells were transduced with the titered viral supernatants. The microscopic 
picture shows a representative 32D cell, when using fluorescence light green color after 
HA-tag FITC staining appeared (Figure 3.1D). 32D cells showed transgene-positive cells 
by flow cytometry two days after transduction compared to the isotype control (Figure 
3.1E). To conclude, the HA-tag cloning to the ECD of the Mpl receptor is sufficient to 
detect 293T transgene-positive cells after transfection via flow cytometry. Furthermore, 
gamma-retroviral vectors were cloned and showed expression of Mpl via mAb detection 
after retroviral transduction of 32D cells. Transgenic Mpl can now be distinguished from 
the endogenous Mpl receptor for in vivo application.  
 
 
 
 
 
 
Results   
48 
48
 
 
Figure 3.1: Mpl cloning and expression analysis. (A) Schematic structure of the Mpl receptor with signal peptide (SP), 
extracellular domain (ECD, with CRM1 and CRM2 [cytokine receptor homology module]), transmembrane domain (TMD) 
and intracellular domain (ICD) is shown, see also Appendix 6.2. The SP is cleaved off by proteases. The nine-amino-acid-
long HA-tag (hemagglutinine-tag) was introduced between SP and ECD. (B) The Mpl cDNA was introduced into the 
pcDNA3.1 cloning vector from Invitrogen via NotI and BamHI restriction sites. (C) The expressing plasmid was used for 
transfection of 293T cells by calcium phosphate method. Two days after transfection transgene positive cells could be seen 
by flow cytometry analysis after HA-tag-FITC mAb staining. (D) 32D cells were transduced with the viral supernatants 
gained from transfected 293T cells with retroviral vectors. The light microscopic picture shows a representative cell, when 
using fluorescence light green color after HA-tag FITC staining could be seen. (E) 32D cells showed a population of 
transgene positive cells two days after transduction with the retroviral vector as detected by flow cytometry compared to 
isotype control. (F) Transduced IL-3 dependent 32D cells were cultured in different cytokine conditions. Shown are 
transgene positive cells in percent as detected by flow cytometry against time of observation in days. Without (w/o) any 
cytokine substitution cells died only a few days after shifting to the new condition. The difference in survival time of the 
SF91.dnMpl (dominant negative) transduced cells to the SF91.wtMpl (wild type Mpl) and SF91.GFP (green fluorescence 
protein) transduced cells may result from residual IL-3 in the new condition because cells were not washed before applying 
them to the new condition media. In the IL-3 condition all cells survived. Applying Thpo conditions only SF91.GFP and 
SF91.dnMpl transduced cells died after switching to the new conditions. Interestingly, SF91.wtMpl transduced 32D cells 
were now able to proliferate with Thpo substitution only.  
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3.1.2. Mpl expression confers a selective growth advantage to murine bone 
marrow cells  
To assess the potential of a gene therapy for Mpl deficiency we used the gamma-
retroviral vectors expressing murine wild-type Mpl (wtMpl) receptor or green fluorescent 
protein (GFP) as a control. IL-3 dependent 32D cells were transduced with the retroviral 
vectors and cultured in different cytokine conditions (Figure 3.1F).  
 
 
 
Figure 3.2: Vector constructs and experimental setup. (A) The gammaretroviral vectors used in this study are shown. 
Transgenes, either Mpl or GFP, are flanked by the two LTRs. The dnMpl is lacking the ICD with Box 1 and Box 2 for 
kinase binding and the tyrosine residues which are phosphorylated by the kinases. Abbreviations: LTR (long terminal 
repeat), SF (spleen focus forming virus enhancer-promoter), Ψ packaging signal, HA (hemagglutinine tag), ECD 
(extracellular domain), CRM (cytokine receptor homology module), TMD (transmembrane domain), ICD (intracellular 
domain), GFP (green fluorescent protein), wtMpl (wild type Mpl) and dnMpl (dominant negative Mpl). dnMpl is a 
truncated form of Mpl missing the intracellular signaling domain (ICD). (B) The schema of BMT is shown. Lineage 
negative cells were isolated from BM of untreated C57Bl6/J mice. Cells were transduced with retroviral supernatant on two 
following days and transplanted into lethally irradiated recipient mice. Animals were observed for symptoms of disease up 
to eleven months post transplantation or sacrificed when moribund. 
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Transgene expression was regularly measured by flow cytometry. Without (w/o) any 
cytokine substitution SF91.wtMpl (blue) and SF91.GFP (green) transduced cells died 
only a few days after culturing in the new media condition. The difference in survival 
time of the SF91.wtMpl transduced cells to the SF91.GFP transduced cells may result 
from residual IL-3 in the new condition because cells were not washed before applying 
them to the new condition media. In the IL-3 condition all cells survived (Figure 3.1F 
second graph).  
 
#
mice 
number
vector and 
transgene
transgene [%]  
before BMT
observation 
time [d] diagnosis
Exp. 1 18 wtMpl-GFP-mix* 59 - 69 (wtMpl) 34 - 341 15 pancytopenia/MDS
62 - 64 (GFP) 225 1 leukemia (#1)
311 2 d.o.u.c.
Exp. 2 4 SF91.wtMpl 46 180, 196 2 MDS
62, 102 2 leukemia (#2, #3)
Exp. 3 5 SF91.wtMpl 26 66 - 145 5 CMPD
5 SF91.dnMpl 69 61 - 115 5 pancytopenia/MDS
4 SF91.GFP 74 145 4 healthy
Exp. 4 5 SF91.dnMpl 73 54 - 188 5 pancytopenia/MDS
6 SF91.GFP 58 19 - 207 6 healthy
* SF91.wtMpl and SF91.GFP were mixed 1:1 before transplantation  
 
Table 3.1: Performed in vivo experiments. # running number of experiment, mice numbers, vectors and transgenes, 
transgene in percent before BMT, observation time after BMT and diagnosis are listed. Each experiment was an individual 
transplantation experiment using the protocol described in the Materials and Methods section. MDS, myelodysplastic like 
syndrome, d.o.u.c. death of unknown cause, CMPD chronic myeloproliferative disease. 
 
Furthermore, SF91.wtMpl transduced cells were lost or lost the transgene during time. 
Applying Thpo conditions only SF91.GFP transduced cells died after switching to the 
new conditions. Interestingly, SF91.wtMpl transduced 32D cells were able to proliferate 
with Thpo substitution only and selected for transgene positive cells (Figure 3.1F third 
graph). In vitro expression of SF91.wtMpl in the IL-3 dependent myeloid cell line 32D 
rendered these cells responsive to Thpo.  
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Figure 3.3: Retroviral transgene expression in all hematopoietic lineages. (A) The first panel shows the gating strategy 
for platelets (PLT) and erythrocytes (RBC) using logarithmic scale in forward scatter (FSC) and side scatter (SSC). Mice 
transplanted with retrovirally (SF91.GFP) transduced BM cells showed relevant gene marking of GFP in the PB on PLT 
(second panel) and RBC (third panel). (B) Shows the gene marking in the PB of mice receiving BM cells transduced with 
SF91.wtMpl. Mpl expression on PLT (second panel) and RBC (third panel) can be seen. (C) Mice transplanted with 
retrovirally transduced BM cells expressing Mpl showed transgene expression in different lineages of the spleen. The first 
panels show the isotype controls, the second panels represent CD11b and Gr1 and Mpl double positive cells, the third 
panels show the staining for CD19 and CD3 and Mpl double positive cells and the last panels display ckit and Sca1 and 
Mpl double positive cells. Percentages of populations are as indicated. The mouse showed symptoms of disease which may 
explain altered levels of hematopoiesis.  
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Secondly we transplanted lethally irradiated C57Bl6/J mice with SF91.wtMpl and 
SF91.GFP transduced BM cells and analyzed transgene expression by flow cytometry in 
the hematopoietic lineages (Figure 3.2B). Using the logarithmic scale in the forward 
scatter (FSC) and the side scatter (SSC) we gated for platelets (PLT) and red blood cells 
(RBC) (Figure 3.3A, B first panel). Either mice receiving SF91.GFP (Figure 3.3A) or 
SF91.wtMpl (Figure 3.3B) transduced BM cells showed transgene expression in PLT and 
RBC from PB samples. Analyzing the different hematopoietic lineages like myeloid cells 
(CD11b, Gr1 positive), lymphocytes (CD19, CD3 positive) or HSC markers (ckit, Sca1 
positive) transgene expression after transplantation of retrovirally transduced cells could 
be found in all lineages of the spleen by flow cytometry (Figure 3.3C). The analyzed 
mouse showed symptoms of disease which may explain altered levels of the 
hematopoietic lineages in the spleen to steady state hematopoiesis.  
To evaluate the possible competitive advantage of cells ectopically expressing wtMpl, 
SF91.wtMpl-transduced BM cells were transplanted into recipient mice (Exp. 1, 2, 3, 
n=27, Figure 3.2A, B, Table 3.1). Only in Exp. 1 were SF91.wtMpl transduced BM cells 
mixed in a competition assay with SF91.GFP transduced cells at a ratio of 1:1 before 
transplantation (n=18). The percentage of wtMpl and GFP-expressing cells as detected by 
flow cytometry was similar before mixing (Table 3.1) (transgene-positive cells after 
mixing: 18% - 36% wtMpl and 19% - 44% GFP, Figure 3.4A).  
We regularly monitored transgene expression in PB cells after BMT. In all cases of Exp. 
1 except two mice, the percentage of wtMpl-expressing cells increased while GFP-
expressing cells decreased (Figure 3.4A, Wilcoxon test *P=5.7 x 10-5 at six weeks post-
transplantation including the two GFP exceptions). From weeks 6 to 13, wtMpl-positive 
cells rose up to 80% in the PB whereas GFP-positive cells further decreased. It can be 
concluded that BM cells ectopically expressing wtMpl gain a multi-lineage growth 
advantage, probably via enhanced wtMpl signaling. 
According to the growth advantage of SF91.wtMpl-transduced cells, all mice (Exp. 1, 2, 
3) developed erythrocytosis, thrombocytosis and leukocytosis in the first weeks after 
transplantation (Figure 3.4B, C), resulting in a striking reddish appearance of nose and 
paws. Those mice showed an increase of erythropoiesis in the spleen and BM.  
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Figure 3.4: Kinetics and histopathology of wtMpl expressing animals. (A) Percentage (positive cells, pos. cells) of 
transduced PB cells over time after BMT is shown. Mice received a 1:1 mix of SF91.wtMpl and SF91.GFP transduced 
cells in a competition assay. Initially SF91.wtMpl transduced cells showed a growth advantage compared to SF91.GFP 
expressing cells (week 6, *P = 5.7 x 10-5, Wilcoxon test). Subsequently SF91.wtMpl transduced cells and co-existing 
unmodified cells (data not shown) decreased (Exp. 1 and 2, Table 1). (B) PB counts of SF91.wtMpl (dark grey, n=5) 
transplanted animals at 7 weeks post transplantation (Exp. 2, Table 1). All hematopoietic values (WBC, RBC, HCT and 
PLT) were strongly increased compared to SF91.GFP control mice (light grey, n=4, arrow bars indicate SD) (all 
measurements: *P ≤ 0.009, t-test, two tailed, unequal variations). (C) Serial PB counts (SF91 vectors, Exp. 3). WBC, RBC 
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and PLT counts showed strong perturbation of multi-lineage hematopoiesis. SF91.wtMpl transduced BM cells receiving 
animals (blue lines) showed an early increase of hematopoiesis compared to GFP control group (green line, mean of n=4) 
with subsequent decrease. SF91.dnMpl transduced BM cells receiving animals (red lines) had cell reduction in all main 
lineages without initial increase. Mean of GFP group ± SD is indicated as control (light green, n=4). Zero time points 
originate from the analysis of wild-type C57Bl6/J mock mice (n=4): WBC 4.5±1.1 103/µL, RBC 10.1±0.5 106/µL, PLT 
10±54 105/µL, respectively. (D, E, F) Histopathology of SF91.wtMpl expressing mice 20 weeks post transplantation is 
shown. Increase of atypical megakaryocytes in the BM (D), and spleen (E) and atypical neoformation of bone in the spleen 
(F), indicates CMPD. Magnification and staining: (D) 200x, PAS; (E) 400x, HE; (F) 100x, HE. 
 
In some of the animals, the number of mature Mk was elevated within BM and spleen, 
with slightly atypical features in Mk (Figure 3.4D, E). In two mice an excessive increase 
of Mk with numerous giant forms could be detected. One animal presented atypical 
neoformation of the bone in the spleen (Figure 3.4F). The summary of these pathologic 
features in mice with increased multilineage hematopoiesis allows the diagnosis of a 
chronic myeloproliferative disorder (CMPD). For the development of gene therapy, these 
results indicate that the expression of ectopic wtMpl has to be tightly regulated to remain 
normal hematopoiesis. 
 
3.1.3. Leukemias developing in wtMpl expressing mice require insertional 
mutagenesis  
Three out of 27 SF91.wtMpl transplanted mice developed leukemia within a latency of 2, 
3.5 and 7.5 months, respectively. They presented with up to ten times enlarged spleens 
(680 mg to 980 mg) and livers that had a typical cherry red color. Nucleated erythroid 
precursors were found in the blood (Figure 3.5E), compatible with erythroid leukemias. 
The leukemic cells in the spleen were CD71 and TER119 and wtMpl positive as detected 
by flow cytometry (Figure 3.5A). In the spleen, all three animals showed diffuse 
infiltrations of blasts which amounted to 80 – 90% of cells (Figure 3.5C, D). Erythroid 
precursors were also detectable within the lumen of the blood vessels (Figure 3.5E). The 
BM of these animals was infiltrated by a significantly lower amount of blasts which 
exceeded 20% of cells in two of the mice, but amounted to less than 20% in the third. In 
this animal, the BM showed morphologic features of a chronic myeloproliferative 
disorder (CMPD) with marked increase of mature giant Mk (Figure 3.5D).The liver of 
this animal showed an extensive infiltration mainly by immature erythroid precursors 
with only a low amount of myeloid blasts. 
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Figure 3.5: Phenotypic and molecular analysis of erythroid leukemias. (A) Three (#1, 2, 3) out of 27 animals 
transplanted with SF91.wtMpl transduced cells developed erythroid leukemia. Splenocytes were negative for CD11b, Gr1, 
CD3 and CD19 but expressed CD71, TER119 and transgene as compared to the isotype control (Exp. 3, case #3). (B) LM-
PCR and Southern blot analysis showed monoclonality of leukemias. The number of insertion sites ranged from three to 
six. Insertion sites are listed in Table 3.2. Arrows in LM-PCR indicate internal control bands (marker, M). (C, D, E) The 
Histopathology of leukemias is shown. Diffuse infiltration of blasts and atypical megakaryocytes (arrows) in the spleen (C, 
D), infiltration of the liver by erythroid precursors (arrow) and detection of erythroid leukemia within the lumen of the 
blood vessels (arrow) can be observed (E). Magnification and staining: (C, D) 400x, HE; (E) 200x, HE. 
 
Leukemias were clonal as indicated by Southern blot analysis and LM-PCR and 
contained three to six retroviral insertions (Figure 3.5B). In each leukemia one of the 
insertion sites was located in proto-oncogenic common insertion sites (CIS) like Pu.1, 
Fli-1 and Klf-3 (Table 3.2) which are known proto-oncogenes leading to erythroid 
leukemia (Funnell et al., 2007; Kirberg et al., 2005; Schuetze et al., 1993). As a 
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representative sample the whole cDNA of the HA-Mpl construct of mouse #1 was 
sequenced for mutations. No activating mutations responsible for the leukemogenic 
alterations could be found. However, the latency until the onset of leukemia was short 
compared to other reported cases of leukemias induced by insertional mutagenesis taking 
into account that the transgene may influence integration (Modlich et al., 2005; Modlich 
et al., 2008). In addition, all leukemias had an erythroid phenotype, which were rarely 
observed using vectors expressing other transgenes (Modlich et al., 2005). Furthermore, 
erythroid leukemias were also induced by vectors expressing constitutively active Mpl 
mutants, as shown later (Chapter 3.2). This indicates that ectopic wtMpl expression was a 
necessary additional factor for leukemia development. Because wtMpl expression alone 
did not trigger leukemogenic outgrowth in most of the mice (24/27), it can be concluded 
that insertional mutagenesis was an essential cooperating event for induction of leukemia.  
 
mouse 
# gene name
CIS 
(IDDb)
CIS 
(RTCGD) gene ID distance orientation name and function
1 Gphn 268566 -124234 F gephyrin/catalytic activity, protein binding
1 Itgb8 320910 166737 F integrin beta 8/protein binding
1 Pck2 74551 -469 F phosphoenolpyruvate carboxykinase 2/kinase activity
1 Sfpi1 (Pu.1) 6 20375 -773 R SFFV proviral integration 1/transcription factor
2 Fmn1 14260 69609 R Formin 1/DNA, protein binding
2 Gcc1 74375 tbd tbd golgi coiled coil 1/Golgi apparatus
2 Klf-3 6 16599 tbd tbd Kruppel-like factor 3/DNA binding, transcription
3 Dusp22 105352 37701 R dual specific protein 22/phophatase activity
3 Fli-1 2 9 14247 -4905 R Friend leukemia integration 1/transcription factor activity
3 Serping1 12258 -24129 R serine peptidase inhibitor/endopeptidase inhibitor
3 Spflc2 20773 tbd tbd serine palmitoyltransferase, long chain base subunit 2
3 Thsd3 217738 tbd tbd thrombospondin, type I, domain containing 3
3 Ube2l6 56791 681 F ubiquitin-conjugating enzyme E2L 6/ligase activity
 
 
Table 3.2: Retroviral insertion sites (RIS) of leukemogenic animals. Insertions sites identified by LM-PCR in three 
leukemogenic animals transplanted with SF91.wtMpl transduced BM cells are listed. Insertion sites were amplified in 
genomic DNA of the spleen which was the major site of leukemia manifestation. RIS are related to the closest genes. 
Abbreviations: CIS common insertion site, IDDb insertional dominance database, RTCGD retroviral tagged cancer gene 
database, F forward, R reverse, tbd to be determined.  
 
3.1.4. Long term ectopic overexpression of wtMpl leads to pancytopenia 
The 24 mice that did not develop leukemia allowed us to address hematopoietic 
consequences of long-term ectopic wtMpl expression. Despite the initial growth 
advantage of SF91.wtMpl transduced cells and increase in multilineage hematopoiesis by 
wtMpl expression on non-target cells (Figure 3.3A, B, C), many animals gradually 
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developed lethal pancytopenia (n=15) (Figure 3.6A and Figure 3.4A). WBC, RBC, HCT 
and PLT counts steadily decreased until symptoms in transplanted mice became so severe 
(hunched posture, anemic, lethargic) that they had to be sacrificed. WBC counts of 
pancytopenic mice, in comparison to GFP-transplanted control animals, dropped to 50% 
at final analysis. RBC counts and HCT were as low as 20 - 30%. Platelets were more than 
tenfold reduced (Figure 3.6B). Flow cytometry of several lineage markers (Gr1, CD11b, 
TER119, CD71, CD19, CD3, ckit, Sca1, CD41, CD45) showed no alterations towards a 
specific lineage (data not shown). In conclusion, ectopic overexpression resulted in 
pancytopenia in most of the animals (17/22) observed long-term, following the initial 
increase of hematopoiesis (CMPD). The cell loss even involved co-existing untransduced 
hematopoietic cells, or GFP-transduced cells (Exp. 1) indicating consumption of an 
essential niche factor. 
 
3.1.5. Pancytopenia after transplantation is induced by a dominant negative 
effect 
As the development of pancytopenia even involved unmodified and GFP-expressing 
control cells, we addressed whether this effect was due to wtMpl signaling. We therefore 
constructed a truncated, dominant negative Mpl receptor (dnMpl) that could bind Thpo 
but lacked the intracellular signal transduction domain (Figure 3.2A, Appendix 6.2). The 
dnMpl receptor contained an artificial stop-codon at position bp 1563 resulting in a 
truncated cDNA. This should result in an early stop of transcription and deletion of the 
active signaling parts in the intracellular domain. dnMpl was shown not to induce any 
Thpo mediated signals (Alexander et al., 1996a). We confirmed that SF91.dnMpl 
transduced 32D cells could not grow Thpo-dependently while SF91.wtMpl-transduced 
32D cells could (Figure 3.1F third panel). Lin- BM cells (Mpl+/+) were transduced with 
SF91.dnMpl and transgene-expressing cells, sorted by magnetic beads (MACS) were 
plated into methyl cellulose. dnMpl expression inhibited Thpo-dependent growth of 
Mpl+/+ cells, despite their endogenous Mpl receptor, confirming previously reported 
results with a similar truncated mutant Mpl receptor (Millot et al., 2002) (Figure 3.6C).  
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Figure 3.6: Long-term analysis of mice transplanted with cells ectopically expressing wtMpl or dnMpl. (A) After the 
initial increase of most PB cell counts, cells in all lineages decreased over time and pancytopenia developed (Exp. 1, n=9). 
(B) Blood counts of pancytopenic animals from SF91.wtMpl and SF91.dnMpl groups with SF91.GFP control are shown. 
Groups are represented by: SF91.GFP (light grey, n=11), SF91.wtMpl (dark grey, n=15, two animals died unexpected and 
escaped detailed analysis) and SF91.dnMpl (medium grey, n=10) (summary of all experiments). Error bars represent SD 
(*P ≤ 0.02, t-test, two tailed, unequal variations). (C) Colony forming capacity of transduced Lin- Mpl+/+ BM cells. Cells 
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were sorted for transgene expression by MACS (magnetic associated cell sorting) and plated into full methyl cellulose 
conditions or Thpo methyl cellulose only. SF91.GFP transduced cells were able to form colonies under Thpo conditions 
whereas SF91.dnMpl transduced BM cells could not form any colonies. The experiment was performed in duplicates. (D) 
Western blot and EMSA of protein lysates from 32D transduced cells with SF91.wtMpl, SF91.dnMpl and SF91.GFP 
control are shown. GFP expressing cells presented no activation by Thpo stimulation, whereas wtMpl expressing cells 
showed to be stimulated with Thpo only. In SF91.dnMpl transduced cells no signal could be detected after Thpo 
stimulation (phos: Ab for phosphorylated protein). (E) Survival chart of mice transplanted with SF91.wtMpl (n=23, Exp. 1, 
2 and 3) or SF91.dnMpl (n=10, Exp. 3 and 4) transduced cells which became cytopenic is displayed. dnMpl expressing 
animals had a statistically significant shorter latency to develop pancytopenia compared to wtMpl expressing animals (Log 
Rank test: *P ≤ 0.0006). Four SF91.wMpl animals were sacrificed for final analysis without symptoms of cytopenia (but 
CMPD, Exp. 3) at 20 weeks post transplantation. 
 
Thpo stimulation of SF91.dnMpl-transduced 32D cells showed no STAT3, STAT5, 
ERK1/2 and AKT activation in contrast to wtMpl-transduced cells, as analyzed by 
Western blot and EMSA (Figure 3.6D). It can be concluded that dnMpl does not confer 
survival or proliferation signals after Thpo stimulation and that it also inhibits the 
signaling of the endogenous Mpl receptor.  
Interestingly, animals receiving SF91.dnMpl-transduced BM cells developed the same 
pancytopenic phenotype as mice that received SF91.wtMpl-transduced cells (Exp. 3, 4). 
Blood counts were severely reduced (Figure 3.6B). However, dnMpl mice did not 
develop the initial CMPD as was observed in mice transplanted with SF91.wtMpl-
transduced cells (Figure 3.4C, red lines). Accordingly, the mortality of SF91.dnMpl 
transplanted mice was more rapid compared to SF91.wtMpl-transplanted mice (survival 7 
weeks to 6 months, *P ≤ 0.0006, Log Rank test Figure 3.6E). This strongly suggests that 
the lethal pancytopenia was not due to increased Thpo signaling but caused by a 
dominant negative effect of Thpo binding to the ectopically expressed wtMpl. However, 
the initial increase of erythropoiesis and thrombopoiesis was not observed in dnMpl-
expressing mice and was therefore a specific effect of signaling via the ectopically 
expressed wtMpl. 
Together, these data suggest that ectopic expression of Mpl induced an initial increase of 
multi-lineage hematopoiesis (CMPD) that depleted the hematopoietic niche from Thpo 
that is essential for survival of HSC, including the unmodified population.  
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3.1.6. Pancytopenic mice develop an MDS-like bone marrow failure 
syndrome 
Mice that were sacrificed due to pancytopenia were subjected to detailed pathological 
analysis. There were no macroscopic alterations observed and spleen weights ranged 
between 70 mg and 218 mg. The BM was normo- to slightly hypocellular. All mice 
showed a dysmyelopoiesis (dysmegakaryopoiesis and dysgranulopoiesis) with reduction 
of hematopoiesis within the spleen. Also, a variable degree of reduction as well as 
incomplete maturation of erythroid cells and Mk within the BM could be observed. In all 
animals, mature Mk were reduced to a variable extent with relative increase of atypical 
micromegakaryocytes with a hypolobulated round nucleus (Figure 3.7A, B). Dysplastic 
features were rarely detected in erythroid and granulocytic precursors, and they amounted 
to less than 5% of cells. However, in 15 animals, more than 5% myeloblasts were 
detected within the spleen or the BM. Furthermore, a few histiocytes with phagocytosis 
of erythrocytes or nucleated myeloid cells were detectable within the BM or spleen in the 
majority of animals (Figure 3.7B). In seven animals, the number of mast cells was 
moderately to extensively increased within the BM (Figure 3.7C). There was no 
difference in the degree of dysmyelopoiesis between the wtMpl and dnMpl-expressing 
groups (Figure 3.7D, E, F). In contrast to human MDS that arises from a single MDS 
clone (Tiu et al., 2007), the BM of pancytopenic wtMpl-expressing mice appeared 
oligoclonal as analyzed by LM-PCR (Figure 3.7G). The clonality was similar to the GFP-
expressing control group (5 months post transplantation, Exp. 3). It can be concluded that 
selection for an MDS clone did not occur in our experimental system. Although the 
morphologic alterations of hematopoiesis did not exactly match those detectable in 
human MDS, a lot of similarities were observed that allow the description of an “MDS-
like” disorder. 
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Figure 3.7: Histopathology of MDS-like disease. BM samples from the sternum of SF91.wtMpl (A, B, C), and 
SF91.dnMpl (D, E, F) transplanted mice are displayed (detected cases from all experiments). (A) Dysmegakaryopoiesis 
with increased number of atypical micro-megakaryocytes (arrows), (B) histiocytes with erythrocytophagocytosis and one 
atypical micro-megakaryocyte, (C) atypical mast cell proliferation (arrows), (D, E) dysmegakaryopoiesis with atypical 
micro-megakaryocytes and one histiocyte with erythrocytophagocytosis and (F) slight increase of mast cells indicate MDS 
like syndrome. Magnification and staining: (A) 200x, HE; (B) 400x, HE; (C) 200x, Giemsa; (D) 400x, HE; (E) 200x, PAS; 
(F) 200x, Giemsa. (G) LM-PCR data of pancytopenic SF91.wtMpl and SF91.dnMpl transduced BM cells receiving mice 
with GFP control group. Pictures suggest oligoclonal repopulation of MDS animals. Lanes of LM PCRs have not been 
identified. Bands appearing in water control can be due to primer dimerization.  
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3.1.7. Pancytopenic mice have reduced numbers of LSK, CMP and MEP 
cells 
We next asked whether the dysplastic features in the BM altered the HSC compartment. 
We therefore analyzed the lineage-negative, Sca1 and ckit-positive faction (LSK) in the 
BM of pancytopenic animals in which the majority of HSC resides. The LSK fraction in 
the BM of wtMpl and dnMpl-expressing pancytopenic mice was remarkably reduced 
(Figure 3.8A, C). However, mice transplanted with SF91.wtMpl-transduced BM and 
analyzed after 20 weeks (proliferation state, CMPD) showed a normal to slightly 
increased number of LSK cells compared to mice transplanted with GFP-transduced 
control cells (Figure 3.8A, C).  
We then addressed the question whether the decrease of LSK cells resulted in the 
decrease of the progenitor cell populations. Therefore, the Lin-, Sca1-, ckit+ (LK) fraction 
of the BM was analyzed in detail. Alterations in the percentages of the common myeloid 
progenitors (CMP), granulocyte macrophage progenitors (GMP) and megakaryocyte 
erythroid progenitors (MEP) were found. Pancytopenic animals (wtMpl and dnMpl) 
showed reduction in all progenitor fractions with the strongest decrease in CMP (0.5% ± 
0.2%, n=3 vs. GFP 6.5% ± 3.8%, n=3) and MEP (0.9% ± 0.9% vs. GFP 6.0% ± 1.6%) 
(Figure 3.8B, D). Those progenitor fractions are the main site of Mpl signaling under 
physiological conditions and therefore expected to suffer most from Thpo depletion. 
During the stage of increased hematopoiesis (CMPD) in mice transplanted with 
SF91.wtMpl-transduced cells GMP counts were significantly higher compared to the 
GFP control group (Figure 3.8B, D). Alterations of CMP and MEP populations were 
more moderate (Figure 3.8D). Percentage of wtMpl-positive cells in CMPD animals in 
the LK fraction could be detected with a mean of 65 ± 35% (n=4) in contrast to 
pancytopenic animals with a mean of 32 ± 38% (n=3). The early increase in 
hematopoiesis in the wtMpl groups after transplantation was therefore most likely based 
on an increased proliferation of HSC and progenitor fractions, whereas animals that 
developed pancytopenia (wtMpl and dnMpl) showed a massive decrease in all of these 
fractions. Further analysis of BM cells from transplanted animals in CFU colony-forming 
assays in cytokines containing methyl cellulose revealed a growth disadvantage by 
reduced colony numbers for cells obtained from SF91.wtMpl-transplanted mice (n=4) 
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versus those obtained from SF91.GFP-transplanted mice (n=4) 20 weeks post 
transplantation (Figure 3.8E). 
 
 
 
Figure 3.8: Phenotypic analysis and mechanism of pancytopenia. (A, C) LSK (Lin-, Sca1+, ckit+) BM cells from 
transplanted animals were analyzed. SF91.wtMpl vector treated mice 20 weeks post transplantation (Tx) in CMPD state 
(n=4) had a similar proportion of LSK cells compared to the GFP controls (n=3, 20 weeks post Tx). Pancytopenic animals 
transplanted with SF91.wtMpl (n=3, at 11, 19, 28 weeks post Tx) and SF91.dnMpl (n=3, at 8, 10, 24 weeks post Tx) 
transduced cells showed a reduced proportion of LSK cells (Exp. 1, 2, 4). (A) FACS blots show one example of each 
group, and (C) graph shows FACS data of mean ± SD of LSK fractions (*P ≤ 0.03, t-test, two tailed, unequal variations). 
(B, D) Cells from the LK (Lin-, ckit+, Sca1-) fraction were analyzed for common myeloid progenitors (CMP), granulocyte 
monocyte progenitors (GMP) and megakaryocyte erythrocyte progenitors (MEP). (B) The GMP fraction in CMPD mice 
(n=4) was significantly higher compared to the GFP control (n=3). CMP and MEP in pancytopenic animals (wtMpl n=1, 
dnMpl n=2) were reduced. (D) FACS data of progenitor fractions are shown as mean ± SD. GFP n=3, CMPD n=4, panc. 
n=3 (*P ≤ 0.03, t-test, two tailed, unequal variations). (E) CFU of whole BM samples from SF91.wtMpl expressing BM 
cells receiving animals (n=4) at CMPD state and SF91.GFP expressing BM cells receiving control animals (n=4, mean ± 
SD) (20 weeks post Tx, Exp. 3). wtMpl group has a significant disadvantage in colony forming capability in full media 
compared to the GFP control animals (*P ≤ 0.04, t-test, two tailed, unequal variation). (F) Thpo plasma levels from PB in 
transplanted animals were determined. The SF91.GFP (n=5, Exp. 3 and 4) group had normal platelet counts and Thpo 
levels from 300 pg/mL to 800 pg/mL. Mice receiving SF91.wtMpl (n=6, Exp. 1) expressing cells showed severely reduced 
platelet counts but animals had similar Thpo levels compared to the SF91.GFP group. Samples were taken from wtMpl 
group at 24 weeks post Tx and GFP group at 7 and 12 weeks post Tx. 
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3.1.8. Transplanted animals show alterations in serum Thpo levels 
Physiologic THPO levels are regulated by MPL expression on PB thrombocytes 
(Kaushansky, 2005). We therefore investigated the effects of ectopic overexpression of 
wtMpl Thpo plasma levels. The retroviral expression resulted in high wtMpl levels on 
almost all leukocytes and red cells in addition to the platelet wtMpl (Figure 3.3A, B, C). 
A down regulation of Thpo plasma levels would be expected. SF91.wtMpl-transplanted 
animals showed reduced numbers of platelets compared to SF91.GFP-transplanted 
animals (Figure 3.8F). Low platelet numbers would be expected to result in high Thpo 
levels. However, wtMpl-expressing mice with low platelet counts showed Thpo levels 
similar to those of GFP-expressing mice with regular platelet levels. This indicates 
binding of the ligand on non-Thpo signaling target cells, e.g. erythrocytes expressing 
ectopic wtMpl. These findings support the hypothesis that the ectopic wtMpl competes 
with the endogenous Mpl for the ligand.  
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3.2.                                                                      
Mpl receptor design can be an alternative therapeutic 
approach for CAMT to increase the HSC compartment 
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3.2.1. Constitutively active Mpl receptor mutants induce acute leukemia  
Addressing a possible gene therapy for CAMT, we applied an extensive risk assessment. 
Therefore, we asked the question which effects an Mpl receptor gaining constitutively 
active mutations induces in hematopoiesis. Point mutations can occur during reverse 
transcription. To mimic such an event we constructed a constitutively active Mpl (caMpl) 
mutant as previously described by (Alexander et al., 1995).  
 
 
 
Figure 3.9: Vector and transgene constructs. LTR driven vector backbones were used in this part of the study to express 
several truncated Mpl receptors. RRE describes the rev responsive element from the human immunodeficiency virus. 
Different truncated versions of the constitutive active Mpl (caMpl) receptor were cloned into the SF91 backbone and 
further analyzed in vitro and in vivo. Abbreviations: wtMpl wild type Mpl, caMpl constitutive active Mpl, ntMpl 
constitutive active with no Thpo binding Mpl, nrMpl constitutive active with no Ras signaling Mpl, cnnMpl constitutive 
active with no Thpo binding and no Ras signaling Mpl, LTR long terminal repeat, SF spleen focus forming virus enhancer-
promoter, Ψ packaging signal, HA hemagglutinine tag, ECD extracellular domain, CRM cytokine receptor homology 
module, TMD transmembrane domain and ICD intracellular domain, SD splice donor, SA splice acceptor, RRE rev 
responsive element.  
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One single point mutation in the serine codon t-c-a changes the aa configuration to 
cystein t-g-a. Thereby a permanent disulfide bond at aa position 403 is introduced which 
allows the constant homodimerization of two Mpl monomers without Thpo binding and 
results in constitutive receptor activity (Appendix 6.2). The LTR-driven gamma-retroviral 
vector SF91 was used as a backbone to express the protein (SF91.caMpl) (Figure 3.9). 
32D cells transduced with SF91.caMpl render these cells factor-independent in vitro 
(Figure 3.10A). caMpl expressing cells were able to proliferate w/o any cytokine 
substitution, whereas GFP-expressing control cells died after some days.  
 
#
mice 
number
vector and 
transgene
transgene [%] 
before BMT
observation 
time [d]
spleen weight 
[mg] diagnosis
Exp. 5 3 SF91.caMpl 79 20 - 22 721 - 831 3 non lymphatic neoplasia
Exp. 6 5 SF91.caMpl 74 19 - 21 485 - 872 5 non lymphatic neoplasia
6 SF.RRE.caMpl > 50 42 - 112 414 - 498 4 non lymphatic neoplasia
139 233 1 B-cell phenotype
209 101 1 hypoplasia/MDS
6 SF91.GFP 47 21 and 207 67 - 100 6 healthy
Exp. 7 2 SF91.caMpl 60 12 - 14 248 - 472 2 non lymphatic neoplasia
5 SF91.cantMpl 48 15 - 21 422 - 792 5 non lymphatic neoplasia
5 SF91.canrMpl 43 12 - 224 59 - 162 4 hypoplysia (no neoplasia)
1 d.o.u.c.
Exp. 8 5 SF91.canrMpl 26 - 133 189 5 hypoplasia (no neaplasia)
5 SF91.cnnMpl 37 - 201 100 4 prolonged engraftment
156 1 irr. leukemia
5 SF91.cantMpl 23 588 1 non lymphatic neoplasia
13 - 33 83 - 133 4 engraftment failure
 
Table 3.3: Performed in vivo experiments. # running number of experiment, mice numbers, vectors and transgenes, 
transgene in percent before BMT, observation time of mice after BMT, spleen weights and diagnosis are listed. Each 
experiment was an individual transplantation experiment using the protocol described in the Materials and Methods section. 
MDS myelodysplastic-like syndrome, irr. leukemia irradiation derived leukemia, d.o.u.c. death of unknown cause. 
 
Downstream pathway signaling studies of the Mpl receptor by Western blot and EMSA 
revealed that signaling pathways were active even without cytokine stimulation. We 
could also detect a hypersensitivity of caMpl to Thpo stimulation.  
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Figure 3.10: In vitro and molecular analysis of caMpl mutants. (A) IL-3 dependent 32D cells were transduced with the 
retroviral vector and cultured in different cytokine media conditions. Shown are transgene positive cells in percent as 
detected by flow cytometry against time of observation in days. Without (w/o) any cytokine substitution SF91.GFP 
transduced control cells were not able to survive. All other constitutive active mutants could proliferate and selected for 
transgene expressing cells. Using IL-3 substitution all cells expressing the different transgenes were able to proliferate. The 
shorter line for SF91.RRE.caMpl (RRE) transduced cells is due to a shorter observation time. Under Thpo conditions all 
cells receiving one of the constitutive active Mpl constructs could proliferate. Only the GFP expressing control cells died. 
The shorter line for SF91.RRE.caMpl (RRE) transduced cells is due to a shorter observation time. (B) CFU-E colonies 
were derived from the caMpl mutant without any cytokine substitution after 48 hours. caMpl transduced Lin- BM cells 
were able to form colonies even without EPO. (C) Western blot data of different Mpl mutants are displayed. 32D cells were 
transduced with the vector and cultivated to suitable amount of cells. Protein lysates were prepared and analyzed by 
Western blot analysis. caMpl transduced 32D cells showed weak activation even w/o cytokine stimulation compared to the 
GFP control cells. After Thpo stimulation caMpl expressing cells displayed even stronger activation than the GFP control. 
The ntMpl mutant could not be stimulated with Thpo. RRE showed the same activation profile as caMpl. The nrMpl 
mutant had strongly reduced Thpo stimulation activity in ERK. (D) Electromobility shift assays (EMSA) were performed 
from the same protein lysates to analyze the activation of STAT3 and STAT5. SF91.caMpl transduced cells showed a slight 
activation w/o cytokines and a strong signal after stimulation with Thpo. The SF91.ntMpl transduced cells showed no 
signal after Thpo stimulation. Cells transduced with the SF91.RRE.caMpl vector behaved similar as caMpl expressing 
cells. The SF91.nrMpl transduced cells showed moderate activation after Thpo stimulation in STAT5 and strong activation 
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in STAT3 compared to IL-3 stimulation. Bands in STAT5 from the nrMpl construct ran slightly higher in the gel. 
Supershift can confirm if these are the real STAT5 activated bands or artifacts. (E) Blots represent EMSA Supershift 
controls for specificity of STAT3 and STAT5 activation. Arrows indicate supershift. Abbreviations: T Thpo, w/o without 
any cytokine, IL-3 or Thpo stimulation. The second lower band in p-AKT is due to unspecific binding to IgG as per 
manufacturer, p = Ab against phosphorylated protein, FP free probe.  
 
Besides hypersensitivity, there is also a second possibility that caMpl expression mediates 
stronger transgene signals due to the additional supra-physiological receptor molecules 
per cell. In addition to the Akt-specific signal (top band) a nonspecific product was 
detected by the antibody (lower band) as reported by the manufacturer (Figure 3.10C, D). 
Specificity of STAT3 and STAT5 activation in the EMSA was shown by supershifts 
(arrows indicate supershift) (Figure 3.10E). By plating caMpl-transduced BM cells into 
methyl cellulose, CFU-E colonies could be detected after 48 h without any cytokine 
substitution (even without EPO) whereas the wtMpl showed no such colony formation 
(Figure 3.10B).  
 
 
 
Figure 3.11: Macroscopic data and PB data of mice transplanted with the Mpl mutants. (A) Spleen weights in mg of 
different Mpl mutants expressing BM cells transplanted into mice were measured by final analysis. Spleens from caMpl, 
RRE and ntMpl expressing animals were increased (*P < 0.004 t-test, two tailed, unequal variations, in comparison to the 
GFP control). (B) Liver size of caMpl transplanted animals in mg by final analysis. Livers of animals were increased. 
Livers of other Mpl mutant expressing BM cells receiving animals were not weightened (*P < 0.0007 t-test, two tailed, 
unequal variations). (C) The picture shows two enlarged spleens from caMpl transplanted animals by final analysis. Mock 
spleen represents one untreated animal. (D) PB data of mice receiving different vector transduced BM cells were analyzed 
by final analysis. Shown are WBC (log10), RBC, HCT and PLT counts. Arrow bars represent SD (*P < 0.01 t-test, two 
tailed, unequal variations, compared to GFP controls). (GFP n=6, caMpl n=10, RRE n=4, ntMpl n=5 ,nrMpl n=6, cnnMpl 
n=3). 
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Figure 3.12: Histopathology data of caMpl expressing BM cells transplanted mice. (A, B) The pictures show PB 
smears of the caMpl expressing group developing erythroid leukemia after BMT. Dysplastic erythroid precursors are 
marked by arrows. (C, D) Micrographs show PB smears from caMpl expressing group developing myeloid leukemias. 
Dysplastic granulocytes are marked by arrows. (E, F, G) Data show massive infiltration of the BM, liver and spleen by 
erythroid progenitors of caMpl expressing group. Blood vessels in the liver show leukemogenic cells is the PB (F). Spleen 
architecture is completely disrupted (G). (H, I, J) Represents strong infiltration of the BM, liver and spleen by dysplastic 
granulocytes and precursors. Leukemogenic cells are present in the blood (I) and spleen architecture is disrupted (J). 
Magnification and staining: (A, C) 200x, May-Grünwald/Giemsa, (B, D) 1000x, May-Grünwald/Giemsa, (E, F, G, H, I) 
200x, Giemsa, (J) 100x, Giemsa.  
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To study the effects of caMpl expression in vivo, Lin- BM cells were transduced with the 
SF91.caMpl constructs and transplanted into lethally irradiated mice (Exp. 5, 6, 7, Table 
3.3). All mice showed clear signs of leukemia after only two to three weeks and had to be 
sacrificed. Mice showed massive hepatosplenomegaly (spleen: 248 mg to 872 mg, liver: 
2090 mg to 3484) with a typical cherry red color of infiltrated organs (Figure 3.11A, B, 
C). Blood counts revealed a strong increase of WBC with up to 352 x 103 WBC/µL 
(Figure 3.11D). RBC, HCT and PLT were not significantly altered in caMpl-expressing 
animals. Two subgroups of leukemias could be defined. Both groups showed increased, 
dysplastic myeloid and erythroid cells and progenitors in the PB smears (Figure 3.12A, B, 
C, D). However, one group had significantly more erythroid cells and progenitors as 
detected by flow cytometry in the spleen (Figure 3.13A, B, n=7). TER119 and CD71 
single and double positive fractions were increased, whereas myeloid markers like 
CD11b and Gr1 single and double-positive cells and CD45-positive cells were reduced. 
Blood smears showed more erythroid blasts compared to the smear of leukemogenic mice 
of the other group (Figure 3.12A, B, arrows). Histology slides of BM showed dysplastic 
megakaryocytes, infiltration of the liver by leukemogenic blasts and structural disruption 
of the spleen (Figure 3.12E, F, G). This group was therefore named “erythroid leukemia”. 
The second group had increased myeloid cells and precursors in the spleen as detected by 
flow cytometry (Figure 3.13C, n=3). Gr1 and Gr1/CD11b double-positive cells were 
significantly increased compared to the GFP-expressing group. Interestingly, TER119 
and CD71 single and double-positive fractions showed no statistically relevant difference. 
In the PB smears, increased numbers of dysplastic myeloid cells and precursors could be 
seen (Figure 3.12C, D, arrows). Histopathology of the animals presented infiltration of 
leukemogenic blasts in the BM, liver and spleen (Figure 3.12H, I, J). This group was 
therefore named “myeloid leukemia”. To conclude, constitutive activation of Mpl 
receptor signaling is highly leukemogenic and results in hepatosplenomegaly only a few 
weeks after BMT, presenting as either erythroid or myeloid leukemia.   
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Figure 3.13: Flow data analysis of mice transplanted with caMpl expressing BM cells. (A) FACS blots from the spleen 
show that cells are negative for myeloid markers (Gr1, CD11b), B and T cell markers (CD19, CD3) as well as stem cell 
markers (Sca1, ckit). Cells were strongly positive for erythroid markers CD71 and TER119 and transgene (wtMpl). (B) 
Hematopoietic markers in the spleen were analyzed in the caMpl expressing group. Mice showed strong increase of 
erythroid markers (CD71, TER119 single and double positive) why this group was named erythroid leukemia. Arrow bars 
represent SD (*P ≤ 0.04, t-test, two tailed, unequal variations, compared to the GFP control group). Following to name this 
group as “erythroid leukemia”. (C) FACS graphs show the same markers as in B. In this group erythroid markers were 
normal but myeloid markers were increased (Gr1, CD11b single and double positive). Arrow bars represent SD (*P ≤ 0.05, 
t-test, two tailed, unequal variations, compared to GFP control). This group was therefore named as “myeloid leukemia”.  
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3.2.2. caMpl-induced leukemia selects for clones with retroviral vector 
insertions in proto-oncogenes 
Leukemias resulting from caMpl expression in the BM were characterized by different 
molecular biological techniques. Genomic DNA from the infiltrated spleen was purified 
and analyzed by Southern blot. Strikingly, leukemias of SF91.caMpl-transplanted animals 
were found to be oligoclonal and contained 2 to 7 insertion sites (n=9) after only three 
weeks (Figure 3.14A).  
 
 
 
Figure 3.14: Molecular analysis of SF91.caMpl induced leukemias. (A) Southern blot analysis shows retroviral vector 
integrations in the genomic DNA of the spleen of three animals which received SF91.caMpl transduced BM cells. Two to 
seven insertions could be seen for animals #1, #2 and #3. (B) Graph shows vector copy numbers in the spleens of leukemic 
and control animals. (C) Same animals as seen in A are shown for LM-PCR analysis. Bands represent number of retroviral 
insertions. The internal control is marked by an arrow. M marker. (D) SKY analysis of cultured spleen cells from three 
leukemogenic animals was performed to test for chromosomal aberrations. Analysis revealed no chromosomal instability. 
Shown is one representative example. (E) LM-PCR analysis of animals transplanted with SF91.GFP transduced BM cells 
in a time dependent manner is shown. First three mice were sacrificed after 3 weeks and showed no clonality after that 
time. Latter three animals where sacrificed after six months and presented oligoclonal dominance. Bands in the H2O control 
lane can be explained by primer dimerization. The internal control is marked by an arrow. 
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The mean retroviral vector marking in the BM quantified by qPCR in genomic DNA 
ranged from 1.14 to 5.49 and thereby resembles the data obtained by SB (Figure 3.14B). 
LM-PCR showed a similar picture of clonality as SB and qPCR (Figure 3.14C). To 
exclude leukemia development resulting from chromosomal aberrations, we performed 
Spectral Karyotype (SKY) analysis on three leukemogenic animals. No chromosomal 
aberrations could be detected in these analyzed samples (Figure 3.14D). Because 
mutations in the karyotype of the animals were obviously not the reason for the leukemia 
development, we did no further karyotype analysis on the other animals. To examine 
whether the selection of dominant clones was due to caMpl- expression, we analyzed BM 
samples of mice transplanted with SF91.GFP control vector-transduced BM cells, 
sacrificed at two different time points. GFP-expressing control animals analyzed for 
clonality by LM-PCR after three weeks showed polyclonality. However, GFP-expressing 
mice after six months post-transplantation showed clonal selection (Figure 3.14E). It can 
be concluded that clonality in leukemogenic animals after three weeks latency resulted 
from the expression of the mutated Mpl receptor. Comparison of insertion sites recovered 
from leukemic caMpl expressing mice with insertion sites of the RTCGD (retroviral 
tagged cancer gene database) (Akagi et al., 2004) and IDDb (insertional dominance 
database) (Kustikova et al., 2007) revealed a preference for insertions in possible proto-
oncogenes (Table 3.4, Appendix 6.3). Table 3.4 shows a list of insertion sites with 
surrounding genes in 150 kbp distance. Orientation of vector insertion is marked F 
(forward) and R (reverse). Distance of LTR to transcription start site is displayed in 
negative numbers (5’ site of gene transcription start site) and positive numbers (3’ site of 
gene transcription start site). 77 insertions were found with 23 common integration sites 
(30%, CIS) as analyzed via RTCGD and IDDb. Whereas it has to be considered that CIS 
with a match of only 1 or 2 hits in one of the databases is not directly an oncogene. Most 
of the insertion sites detected are positioned closely to the transcription start site of genes, 
assuming a regulatory effect of vector enhancer-promoter elements on the expression of 
the host gene (Wu et al., 2003). Because of the fast leukemia development, insertional 
mutagenesis seems not to be the only reason for oncogenicity. However, it could have an 
influence on the clonal dominance or the phenotype of the leukemia. The other reason for 
the leukemia development must be the constitutively active Mpl mutation.   
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3.2.3. Reduced expression level of caMpl prolongs the latency of phenotype 
development (RRE.caMpl) 
To address the question whether caMpl expression levels correlate with leukemia 
development, we constructed an SF91.caMpl-expressing vector that conferred a ten-fold 
lower expression level (SF91.RRE.caMpl). The reduced expression is based on the 
introduction of the rev responsive element (RRE) from the human immunodeficiency 
virus HIV-1 at 5’ position of the transgene into the vector (Figure 3.9). The RRE element 
in HIV binds to the rev protein and thereby mediates nuclear export of the viral RNA. 
The reduced expression level in our vector system is most likely due to the longer 5’UTR 
region, reduced splicing capacity (Kraunus et al., 2006) and an own upstream open 
reading frame (ORF) in the RRE element before the transgene ORF. Reduced expression 
levels were analyzed by flow cytometry on SC1 cells (Figure 3.15A). 32D cells 
transduced with the low expressing mutant still grew factor-independently (Figure 
3.10A). Activation of Mpl downstream pathways in Western blot and EMSA was similar 
to that observed in SF91.caMpl-transduced 32D cells (Figure 3.10C, D).  
Animals transplanted with BM cells transduced with SF91.RRE.caMpl had a prolonged 
disease latency compared to animals receiving caMpl-transduced cells. The first animal 
developed leukemia after 6 weeks, while other animals survived as long as 7 months 
(Figure 3.15B). Mice which developed leukemia in the earlier timeframe (up to 20 weeks) 
displayed the same phenotypes as animals receiving cells with high expression of caMpl 
with hepatosplenomegaly (spleen: 101 mg to 498 mg) and cherry red color of infiltrated 
organs (Figure 3.11A), whereby the increase of PB cells was even more severe compared 
to SF91.caMpl-transplanted mice. Not only were WBC strongly increased but also RBC 
and HCT showed a statistical significant increase (Figure 3.11D). One animal developed 
a B-cell proliferation with a major fraction of CD19-positive cells as detected by flow 
cytometry. BM, liver and spleen were severely infiltrated by erythroid and myeloid blasts 
like the caMpl-expressing animals (Figure 3.15C, D, E). The BM was hypercellular 
(Figure 3.15C), infiltration of blasts in the blood vessels could be seen in the liver (Figure 
3.14D) and the architecture of the spleen was totally disrupted (Figure 3.15E). 
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Figure 3.15: Analysis of RRE vector mutant. (A) Flow data of rev responsive element (RRE) vector (SF91.RRE.caMpl) 
compared to normal SF91 vector backbone (SF91.caMpl) in SC1 cells are shown. Histogram presents one log10 reduction 
of fluorescence intensity by introducing the RRE element into the vector backbone. (B) Graph represents the survival of 
caMpl-expressing mice compared to RRE construct and GFP control. The caMpl group died after only three weeks post 
transplantation. The RRE group prolonged the latency until 209 days. The GFP group survived long term. (C, D, E) 
Infiltration of the BM, liver and spleen from animals transplanted with cells transduced with the RRE vector construct 
showed dysplastic cells, erythroid progenitors and myeloid cells. (C) BM is hypercellular, (D) blood vessels in the liver 
show infiltration of blasts in the PB and (E) spleen architecture was disrupted. Magnification and staining: (C, D) 200x, 
Giemsa, (E) 100x, Giemsa. 
 
Interestingly, one animal which had a strongly prolonged latency, showed signs of 
pancytopenia as was seen from the expression of wtMpl and dnMpl receptor (Chapter 
3.1). PB counts were as low as: WBC 0.5 x 103/µL, RBC 1.86 x 106/µL, HCT 9.5% and 
PLT 18 x 103/µL. Here the constitutively active signaling of caMpl seemed to be so weak 
that the dominant negative effect of the Mpl receptor, derived from Thpo trapping, 
became the dominant effect compared to the constitutively active signaling. Taken 
together, leukemia development was dependent on transgene expression and lower 
expression levels resulted in prolonged latency or even no leukemogenic outcome in one 
animal.  
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3.2.4. Leukemia development is independent of Thpo binding (ntMpl) 
As a next step, we addressed the influence of the dominant negative effect of ectopic Mpl 
expression seen in the wtMpl and dnMpl-transplanted animals on leukemia induction by 
caMpl (Chapter 3.1). We constructed a constitutively active mutant that lacked the Thpo 
binding domain (Sabath et al., 1999) (Figure 3.9). This was expected to render ntMpl 
signaling independent of the Thpo hypersensitivity seen by caMpl in Western blots and 
EMSA and eliminate the dominant negative effect of ectopic Mpl expression via Thpo 
trapping.  
 
 
 
Figure 3.16: caMpl induced leukemias do not require the Thpo binding domain. (A) Survival chart of caMpl-
expressing animals versus ntMpl-expressing mice is displayed. There was no change in time of survival resulting from the 
lack of the Thpo binding domain. (B, C, D) Histopathology of ntMpl group showed BM, liver and spleen. All organs had 
massive infiltrations of leukemic cells. (B) BM showed an increased amount of erythroid progenitors, (C) liver and blood 
vessels were infiltrated by erythroleukemic cells, (D) spleen architecture was disrupted and showed infiltration of 
leukemogenic cells. Magnification and Staining: (B, C) 200x, Giemsa, (D) 100x, Giemsa.  
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Two fragments of the caMpl receptor were derived by PCR, one fragment containing the 
signal peptide and the HA-tag from aa 1 (Met) to 36 (Gln) and the second one coding for 
the truncated extracellular domain, transmembrane region and intracellular domain from 
aa 284 (Gly) to 635 (Pro). The serine to cystein mutation at position aa 403 (a → c) 
resulting in the constitutive activation remained (Figure 3.9, Appendix 6.2). 32D cells 
transduced with the mutant constitutively active receptor that is unable to bind Thpo 
(ntMpl) showed a similar factor independent proliferation as 32D cells transduced with 
caMpl (Figure 3.10A). The signal activation in EMSA and Western blots without 
cytokine stimulation was hardly detectable, but the hypersensitivity seen before with 
normal caMpl was clearly missing (Figure 3.10C, D). Mice receiving BM cells 
transduced with the ntMpl mutant showed the same hepatosplenomegaly as mice 
receiving caMpl-expressing BM (Figure 3.11A). PB counts showed a strong increase in 
WBC and no significant alterations in the RBC, HCT or PLT (Figure 3.11D) similar to 
the caMpl that is still able to bind Thpo. Animals receiving BM cells transduced with the 
ntMpl mutant showed the same latency as mice transplanted with caMpl transduced BM 
cells (Figure 3.16A). Histopathology revealed infiltration of leukemogenic blasts into the 
BM, spleen and liver (Figure 3.16B, C, D). Blood vessels in the liver were severely 
infiltrated by precursor cells (Figure 3.16C) and the spleen architecture was completely 
disrupted (Figure 3.16D). It can be concluded that the leukemia development is 
independent of the Thpo binding. 
 
3.2.5. Deletion mutants (nrMpl, cnnMpl) of caMpl lack the oncogenic 
potential but retain the positive proliferation effect  
We then asked whether it was possible to design receptor mutants which retain the 
proliferation effect of caMpl but lack the oncogenic potential. Such receptor mutants 
could be used to expand the HSC population for CAMT gene therapy. They should 
submit proliferation signals ligand-independently and do not have any oncogenic signals 
by shutting off these distinct pathways. We therefore constructed constitutively active 
Mpl receptor mutants that lack the 52 C-terminal aa. This mutant was expected not to 
induce signaling via Ras activation (no Ras Mpl, nrMpl). A further nrMpl mutant was 
constructed by combining the nrMpl mutation with the ntMpl mutation (ca-nr-nt-Mpl, 
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cnnMpl) (Figure 3.9). Both mutants were derived via PCR products of the caMpl 
receptor. An artificial stop codon was introduced at aa position 566 t-g-t (c) to t-g-a (stop) 
resulting in truncated cDNAs (Drachman and Kaushansky, 1997). This leads to a 
truncated intracellular domain that lacks three tyrosine residues important for the 
activation of Ras signaling (Appendix 6.2). 32D cells transduced with either one of the 
caMpl mutants (nrMpl, cnnMpl) showed the factor-independent growth observed before 
with the caMpl receptor (Figure 3.10A). This proves that the truncated receptors still 
mediate a proliferation advantage. In Western blot and EMSA analysis, the specific 
defect in activating the desirable pathways (for Ras, MAPK, ERK1/2) was shown by the 
undetectable ERK1/2 phosphorylation compared to the signaling by caMpl after 
stimulation with Thpo (Figure 3.10C, D). However, Akt stimulation was hardly to be 
seen but activation of STAT3 and STAT5 in the nrMpl mutant was similar the activation 
by IL-3 stimulation. 
Mice were transplanted with Lin- BM cells transduced with nrMpl or cnnMpl vectors as 
performed with the caMpl vector. Interestingly, none of the mice developed leukemia and 
they survived up to six months post-BMT (Figure 3.17A). None of the animals had signs 
of hepatosplenomegaly (Figure 3.11A). However, PB in the nrMpl group showed a 
severe reduction in WBC, RBC, HCT and PLT (Figure 3.11D) most likely resulting from 
the dominant negative effect of Thpo trapping. Subsequently, some of the nrMpl-
transplanted animals died due to pancytopenia as observed in the wtMpl and dnMpl-
transplanted animals (Chapter 3.1). In contrast, mice that engrafted with cnnMpl-
expressing BM cells did not develop pancytopenia as seen in PB counts by finial analysis 
(Figure 3.11D). Spleen sizes were also normal (Figure 3.11A). One cnnMpl-expressing 
animal developed a donor-derived thymus leukemia after five months post-
transplantation. The leukemia was most likely due to the irradiation and thymus cells 
analyzed by flow cytometry were not positive for the transgene cnnMpl. However, most 
of the cnnMpl-expressing animals did not survive long-term, which was probably due to 
insufficient engraftment seen in this specific experiment (Exp. 8). Some animals in this 
experiment had low gene marking and died early of engraftment failure. Therefore the 
experiment should be repeated. 
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Figure 3.17: nrMpl mutant and cnnMpl mutant behave similar. (A) Graph shows survival chart of Ras deletion 
mutants compared to GFP and caMpl group. Animals receiving transduced BM cells with the Ras deletion mutants 
(SF91.nrMpl, SF91.cnnMpl) survived significantly longer than the caMpl expressing mice. (B) BM of the nrMpl group was 
hypocellular and showed no infiltration by leukemogenic progenitors. (C) Liver also showed no signs of infiltration. (D) 
Spleen had normal architecture and showed no sign of infiltration. Magnification and staining: (B, C) 200x, Giemsa, (D) 
100x, Giemsa. (Pictures represent an nrMpl expressing animal).  
 
In summary, it can be concluded that the Ras pathway is one or even the most important 
pathway for oncogenicity in Mpl signaling. Shutting off this pathway could avoid 
potential leukemogenic side effects of aberrant Mpl signaling. The cnnMpl mutant may 
possibly be used to expand the HSC fraction in a transcriptionally regulated promoter 
vector system or by transient expression (Gossen and Bujard, 1992). However, further 
transplantation experiments should be performed to rule out additional possible side 
effects.  
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3.3.                                                                                        
Gene therapy with improved vector constructs shows 
promising results for a curative approach to treat 
CAMT 
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3.3.1. Gamma-retroviral vectors containing the cellular Mpl promoter 
fragment show reduced transgene expression levels 
In our previous experiments we observed that high expression of the Mpl receptor 
induced strong side effects like pancytopenia and MDS-like disorders (Chapter 3.1). To 
overcome these side effects, we used a 512 bp fragment of the ubiquitous low expressing 
promoter of the phosphoglycerate kinase gene (PGK) (Schambach et al., 2006a) and the 2 
kb promoter fragment of the endogenous Mpl receptor (MplP) and compared the 
expression by those promoters with the expression by the SF promoter. All promoters 
were introduced into self-inactivating (SIN) gamma-retroviral vector constructs (Figure 
3.18). The MplP should restrict transgene expression to Mk, HSC and MEP cells (Ziegler 
et al., 2002). 
 
 
 
Figure 3.18: Vector constructs and promoters. Self inactivating (SIN) vectors have a deletion in the U3 region which 
eliminates the strong enhancer-promoter activity. Therefore internal promoters are used to drive the transgene expression. 
Promoters used in this experiment were SF (spleen focus forming virus), PGK (phosphoglycerate kinase) and the 
endogenous Mpl promoter fragment (MplP). Abbreviations: LTR long terminal repeat, Ψ packaging signal, HA 
hemagglutinine tag, ECD extracellular domain, TMD transmembrane domain and ICD intracellular domain, SD splice 
donor, CRM cytokine receptor homology module, wPRE woodchuck hepatitis virus post transcriptional element. 
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When company the GFP-expressing constructs (SIN.SF.GFP, SIN.PGK.GFP and 
SIN.MplP.GFP), a reduced fluorescence intensity was detected via fluorescence 
microscopy (Figure 3.19A) in 293T cells that expressed GFP by MplP promoter 
compared to the PGK and SF promoter. GFP expression levels were then analyzed in 
retrovirally transduced SC1 cells by flow cytometry (Figure 3.19B). The mean 
fluorescence intensity of SC1 cells expressing GFP under the control of the PGK 
promoter was reduced 10-fold compared to the expression levels from the SF promoter 
and the expression by the MplP promoter was further reduced compared to the PGK 
promoter. In conclusion, gamma-retroviral SIN vectors with the internal promoters PGK 
and MplP conferred reduced expression levels in murine fibroblast cells and MplP was 
the lowest expressing promoter, possibly because of its cell type-specific restriction of 
transgene expression. 
 
 
 
Figure 3.19: Virus production of the new vector constructs. (A) SIN vector constructs were transfected into 293T cells. 
Pictures show cell layer in cultures 2 days after transfection. First panel represents light microscope and second panel 
shows same cell layer via fluorescence activation of GFP expressing cells. (B) SC1 cells were transduced for titer 
determination with the supernatants of 293T transfected cells. Flow cytometry blots show GFP positive cells 2 days after 
transduction. Mean fluorescence intensity was reduced of about one log10 from SF to PGK promoter and again from PGK 
to MplP promoter.  
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3.3.2. The Mpl promoter shows a tropism for CD41+ cells 
To address the potential of the differentiation-specific expression by retroviral vectors 
that use the Mpl promoter  (SIN.MplP.GFP), we transduced Lin- BM cells of wild-type 
C57Bl6/J mice and compared the expression of GFP to the expression driven by the SF 
promoter in gamma-retroviral SIN vectors (SIN.SF.GFP) in the CD41+ fraction 
resembling Mk and their precursors. The ubiquitously expressing SF promoter was 
expected to confer the same amount of transgene positive cells in every cell lineage. 
However, expression by the MplP should be more specific for CD41+ cells. In both 
cultures, the same numbers of CD41+ cells (29%) were detected in the BM suspension 
four days post-transduction stimulated by the cytokines SCF, IL-3, IL-11, Flt-3L and 
cultivated in StemSpan media (Figure 3.20A, B, first panel). Cells transduced with the 
SF-driven retroviral vector showed high expression of the transgene on 50% of all BM 
cells (Figure 3.20A, second panel). The MplP promoter-driven vector had an about 100-
fold reduced expression level with 10% positive cells using the same MOI (Figure 3.20B, 
second panel). Interestingly, in the GFP-expressing cell population, the MplP construct 
had twice the amount of CD41+ cells compared to the SF promoter (55% to 29%) (Figure 
3.20A, B, third panel). This observation indicated the cell type restricted expression by 
the Mpl promoter compared to the SF promoter.  
We performed further analysis of the differentiation-specific expression by the MplP in a 
second experiment under the same conditions. We determined the ratio of specificity of 
MplP compared to the SF promoter. To calculate the specificity of GFP expression in the 
CD41+ fraction we compared the CD41+/GFP+ cells with the CD41+/GFP+ + CD41+/GFP- 
fraction (Figure 3.20C, D). By dividing this number by the number gained from the 
CD41-/GFP+ fraction compared to CD41-/GFP+ + CD41-/GFP- fraction we determined a 
“differentiation-specific expression factor”.  
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Figure 3.20: Transduction of BM cells with the MplP construct. (A, B) Lin- BM cells harvested from C57Bl6/J wild 
type animals were transduced by same MOI with the viral supernatants of SIN vectors containing the GFP reporter protein 
driven by either SF (A) or MplP (B) promoter. Cells were cultivated for 4 days in StemSpan media containing IL-3, IL-11, 
SCF and Flt-3L. The first row shows flow cytometry data of CD41 positive cells from the whole BM fraction. The second 
row represents the GFP expressing fraction in the whole BM sample, which is significantly reduced in number and 
fluorescence intensity for the MplP expressing construct compared to the SF construct. The third row shows the CD41 
positive cells in the GFP expressing fraction. For the SF promoter it was the same amount whereby it was about twice as 
much in the MplP expressing vector constructs. (C, D) Lin- BM cells were transduced and cultivated in the same way as in 
experiment A. GFP expression is shown against CD41 positive cells. The number of CD41/GFP double positive cells was 
similar in both experiments whereas the total amount of GFP expressing cells was different (see explanation Results part 
for details).   
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The differentiation-specific expression factor for ubiquitous promoters would be expected 
to be one because they should mediate the same probability of transgene expression in 
every lineage. For the MplP promoter this factor is expected to be higher than one 
because the amount of GFP-expressing cells in the CD41+ cell population should be 
higher. Interestingly, the differentiation-specific expression factor for the SF promoter 
was even a little bit lower in CD41+ cells with 0.7, whereby the MplP showed a 
significantly higher factor for the expression in CD41+ cells with 3.1. To determine how 
much more specific the MplP in CD41+ cells is compared to the SF promoter, we 
calculated the ratio of MplP specificity to SF specificity, which was 4.5. This means that 
the MplP is about 4 - 5 times more specifically active in CD41+ cells than the SF 
promoter. 
To conclude, in two independent experiments the 2 kb MplP fragment introduced into a 
gamma-retroviral SIN vectors conferred differentiation-specific expression. However, 
expression levels were very low compared to SF promoter. 
 
3.3.3. Differentiation-specific and low Mpl expression reduce the risk of side 
effects in mice after BMT 
In previous experiments we found that an unregulated high expression of the wtMpl 
receptor induced pathologic side effect like CMPD, pancytopenia and MDS (Chapter 
3.1). To further evaluate our hypothesis that the side effects are expression level 
dependent we used the gamma-retroviral SIN vector constructs in a BMT experiment. In 
the next serious of our studies we transplanted SIN.PGK.wtMpl, SIN.PGK.GFP and 
SIN.MplP.wtMpl, SIN.MplP.GFP transduced Lin- BM cells into lethally irradiated wild-
type mice.  
The MplP restricts wtMpl expression to megakaryopoiesis and the early HSC 
compartment whereas the PGK-driven expression is ubiquitous. Both promoters mediated 
greatly decreased transgene expression levels per BM cell as studied in vectors 
expressing GFP (Figure 3.21A). wtMpl expression by the Mpl promoter could hardly be 
detected on primary Lin- cells by flow cytometry. Efficient gene marking in the BM was 
shown by detection of the vector copy number by qPCR (Figure 3.21B). When using the 
PGK promoter, alterations in hematopoiesis could still be observed.  
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#
mice 
number vector and transgene
donor / 
chimerism
recipient / 
chimerism
transgene [%] 
before BMT
observation 
time [d] diagnosis
Exp. 9 4 SIN.MplP.Mpl WT / - WT / - 6 213 4 healthy
4 SIN.MplP.GFP WT / - WT / - 10 213 4 healthy
4 SIN.PGK.Mpl WT / - WT / - 45 84 - 213 4 cytopenic/MDS
4 SIN.PGK.GFP WT / - WT / - 50 213 3 healthy
193 1 irr. leukemia
Exp. 10 4 SIN.SF.wtMpl KO / 45.2 WT / 45.1 36 295 - 355 4 cytopenic/MDS
4 KO / 45.2 WT / 45.1 322 - 355 4 healthy
2 WT / 45.2 WT / 45.1 288, 355 2 healthy
Exp. 11 5 SIN.MplP.wtMpl KO / 45.2 WT / 45.1 3 152 2 healthy
20 - 29 3 no engrfatment
5 SIN.PGK.wtMpl KO / 45.2 WT / 45.1 39 152 1 healthy
62 1 cytopenic
20 - 26 3 no engrfatment
5* SIN.SF.wtMpl KO 45.2 WT / 45.1 33 19 - 29 5 no engraftment
5* SIN.SF.GFP KO 45.2 WT / 45.1 49 8 - 29 5 no engraftment
Exp. 12 5** SIN.MplP.wtMpl KO / 45.2 WT / 45.1 4 5 healthy
5** SIN.PGK.wtMpl KO / 45.2 WT / 45.1 51 5 healthy
5** SIN.SF.wtMpl KO / 45.2 WT / 45.1 36 4 healthy
10 1 no engraftment
5** SIN.SF.GFP KO / 45.2 WT / 45.1 56 4 healthy
7 1 no engraftment
2 KO / 45.2 WT / 45.1 2 healthy
* SIN.SF.wtMpl (n=5) and SIN.SF.GFP (n=5) died of engraftment failure in the first four weeks
** 200,000 KO BM competitors  
 
Table 3.5: Performed in vivo experiments. # running number of experiment, mice numbers, vectors and transgenes, 
donors, recipients and its chimerism, transgene in percent before BMT, observation time after BMT and diagnosis are 
listed. Each experiment was an individual transplantation experiment using the protocol described in the Materials and 
Methods section. Modifications are described in Chapter 3.3. Abbreviations: MDS myelodysplastic like syndrome, irr. 
leukemia irradiation derived donor leukemia. Exp. 12 histology has to be analyzed by a pathologist to confirm that animals 
have no abnormalities in hematopoiesis.  
 
However, the changes were moderate compared to the alteration observed in mice that 
received LTR vector-transduced BM (Chapter 3.1). WBC, RBC and PLT counts were 
significantly altered compared to the GFP controls (Figure 3.21C). Interestingly, 
expression under the Mpl promoter fragment left PB cell counts almost unchanged 
(Figure 3.21C). Cell counts of mice transplanted with SIN.MplP.wtMpl-transduced BM 
cells showed only a moderate increase in WBC counts and no change in RBC and PLT 
counts compared to the animals receiving SIN.SF.GFP transduced BM cells. An MDS-
like feature with high amounts of mast cells could be observed in mice receiving 
SIN.PGK.wtMpl transduced BM cells in histopathology (Figure 3.21D, E) but was absent 
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in mice transplanted with SIN.MplP.wtMpl transduced BM cells. This may result from a 
direct effect of the Mpl overexpression or by an indirect effect of Mpl upregulating other 
factors like SCF or IL-4 which also results in increased mast cell proliferation (Bischoff 
et al., 1999). It can thus be concluded that the restriction of Mpl expression by MplP will 
be of great value for the development of gene therapy for CAMT. 
 
 
 
Figure 3.21: Transgene expression level correlates with side effects. (A) The transgene expression levels by different 
promoters and vector constructs are shown. Expression of two gamma-retroviral self inactivating (SIN) vectors compared 
to SF91.wtMpl transduced Lin- BM cells before transplantation (Exp. 9) are shown. Counts are presented in linear scale 
and transgene expression in logarithmic scale (log10). Constructs expressed either wtMpl or GFP under the control of the 
PGK promoter or the endogenous Mpl promoter (MplP). wtMpl expression driven by MplP was strongly reduced 
compared to SF enhancer-promoter driven vector (SF91) and PGK promoter. (B) Graph shows copy numbers of mice five 
months post transplantation from BM cells. All animals had relevant gene marking. (C) Diagram of the development of PB 
parameters over an observation time of 30 weeks. WBC, RBC and PLT counts were normal for SIN.MplP.Mpl (brown 
lines) transplanted animals compared to GFP control group (mean ± SD, green with light green bar for area of  SD, n=8). In 
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contrast, mice receiving cells expressing wtMpl from the PGK promoter (blue lines) showed severe alterations especially in 
PLT counts (zero time points in both graphs originate from the analysis of wild type C57Bl6/J mock mice (n=4): WBC 
4.5±1.1 103/µL, RBC 10.1±0.5 106/µL, PLT 10±54 105/µL). (D, E) BM of PGK animals by final analysis showed increased 
mast cell proliferation as seen in MDS-like state in wtMpl and dnMpl transplanted animals (Chapter 3.1). Magnification 
and staining: (D) 200x, Giemsa, (E) 400x, Giemsa. 
 
 
3.3.4. Mpl-/- cells can differentiate into megakaryocytes after transduction 
with Mpl-expressing retroviral vectors 
To show that the new gamma-retroviral SIN vector constructs are able to mediate 
therapeutic benefit, we developed a Mk differentiation assay. Lin- BM cells from wild-
type mice were stimulated for 14 days in StemSpan media containing Thpo, SCF, and IL-
6. Cells were then spun on glass slides and stained for histological analysis by May-
Grünwald/Giemsa staining. Lin- BM cells produced a huge amount of Mk using the 
differentiation media (Figure 3.22B, D, E) compared to cells stimulated with the normal 
BM expansion media (StemSpan, IL-3, SCF, IL-11, Flt-3L) (Figure 3.22A, C). 
Furthermore, the Mk-forming capacity of Mpl-/- cells derived from knock-out mice was 
tested. Mpl-/- mice have a disruption of the c-mpl locus by homologous recombination of 
the first five exons resulting in a complete abrogation of Mpl function. Mpl-/- mice have 
unchanged WBC (3.2 ± 0.9 x 103/µL) and RBC (9.0 ± 1.2 x 106/µL) counts but strongly 
reduced PLT counts (71.5 ± 25.8 x 103/µL, n=6) in the PB and about 10 times less Mk 
and HSC in the BM (Alexander et al., 1996b). We transduced Mpl-/- Lin- BM cells with 
the SIN.SF.wtMpl vector construct and cultivated the cells in the Mk differentiation 
media. Cells were found to form Mk 12 days after stimulation (Figure 3.22F, G, H). The 
May-Grünwald/Giemsa staining revealed the multilobed nucleus that forms after 
polyploidization. The enormous size gain of Mk compared to other WBC is clearly seen. 
To conclude, the new vectors could mediate sufficient expression of the transgene to 
drive differentiation in transduced Mpl-/- to Mk as shown in Mk differentiation media.  
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Figure 3.22: Megakaryocyte differentiation assay. (A, C) Lin- BM cells were cultured in StemSpan media containing 
IL-3, IL-11, SCF and Flt-3L for 14 days without transduction. (A) Suspension culture and cytospins (C) show no 
megakaryocytes. (B, D, E) Lin- BM cells were cultured in StemSpan containing Thpo, SCF and IL-6 for 14 days without 
transduction. Megakaryocytes can be seen in suspension culture (B) and cytospins (D). Cytokine conditions drove 
megakaryocyte development. (F, G, H) Lin- BM cells from Mpl-/- (knock out) animals were cultured in the megakaryocyte 
differentiation media (Thpo, SCF, IL-6) for 12 days after transduction with the SIN.SF.wtMpl construct. Megakaryocytes 
can be seen on cytospins after May-Grünwald/Giemsa staining. Magnification: (A, C, F) 200x, (B, D) 400x, (G) 600x, (E, 
H) 1000x. 
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3.3.5. Mpl gene-corrected Mpl-/- cells engraft long-term and are detected in 
the peripheral blood after BMT 
After the promising in vitro results we further tested the new gamma-retroviral SIN 
vector constructs in Mpl-/- BMT experiments. Initial experiments in which gene-corrected 
Mpl-/- BM cells were transplanted into 10 Gy-irradiated Mpl-/- mice did not show long-
term engraftment of BM cells and transplanted recipient mice died soon after BMT. It 
became obvious that Mpl-/- mice were more sensitive to condition regimes than the 
syngenic C57Bl6/J Mpl+/+ mice. To overcome these transplantation problems, we 
transplanted gene-corrected Mpl-/- CD45.2 BM cells into lethally irradiated (10 Gy) 
CD45.1 Mpl+/+ recipient mice. The first group of mice received Mpl-/- Lin- BM cells 
transduced with the SIN.SF.wtMpl vector construct (n=4), the second group received 
untransduced Mpl-/- Lin- BM cells as a negative control (n=4) and finally the last group 
received Mpl+/+ Lin- BM cells as a positive control (n=2) (Exp. 10, Table 3.5). Following 
this strategy, all animals survived the BMT. The Mpl transgene was detectable in the PB. 
We also distinguished between donor (CD45.2) and recipient (CD45.1) cells. 6, 16, 25 
and 39 weeks after BMT PB samples were taken. We measured the CD45.2 (donor) 
fraction and 6 weeks after BMT we found up to 90% CD45.2-positive cells which were 
then decreasing over time until a steady state was reached between 10% and 35% positive 
cells at 39 weeks post transplantation (Figure 3.23A). Interestingly, the Mpl-positive 
fraction in the CD45.2+ cells first increased up to 50% and finally ranged between 10% 
and 40% (Figure 3.23B). PB counts showed no severe alterations for WBC and RBC. 
Interestingly, PLT counts were statistically significantly reduced compared to the control 
group (untransduced Mpl+/+ BM) (Figure 3.23C). Similar to that seen for the LTR-driven 
vectors in Chapter 3.1, Mpl expression was still too high in SIN.SF.wtMpl vectors 
resulting in decreased PLT counts may have prevented a selective advantage in HSC.  
In a subsequent experiment involving the vectors driven by the MplP, PGK and SF 
promoter-expressing wtMpl, most of the animals died shortly after BMT of graft failure 
(Exp. 11). Only two animals in the MplP group and one in the PGK group survived until 
final analysis after five months.  
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Figure 3.23: PB analysis of mice transplanted with wtMpl transduced Mpl-/- cells. (A) Lethally irradiated Mpl+/+ mice 
received either transduced (red, SIN.SF.wtMpl) or untransduced (grey) Lin- Mpl-/- BM cells in a BMT experiment. The 
graph shows the donor fraction (CD45.2 positive cells) in the PB at different time points of observation. Donor cells 
decreased over time until they reached a steady state after about 18 weeks. (B) Graph represents the same PB data as seen 
in A. Stained are the Mpl positive cells via HA-tag in the CD45.2 positive fraction. Despite the decrease of the donor 
fraction in the periphery wtMpl positive Mpl-/- cells increased until they reached a steady state. (C) WBC, RBC and PLT 
from Exp. 10 are displayed (SIN.SF.wtMpl in red, untransduced Mpl+/+ BM cells in grey). WBC and RBC showed no 
alterations whereas PLT counts from wtMpl expressing animals were decreased compared to the control animals (*P ≤ 
0.03, t-test, two tailed, unequal variations). (D) PB data are shown from Exp. 12. WT mice were transplanted receiving 
Mpl-/- competitors. SIN vectors expressing either wtMpl or GFP driven by the SF, PGK or the MplP are shown. WBC and 
RBC data displayed no difference during observation time. PLT data showed a significant difference of PLT counts in the 
PB of MplP and SF promoter wtMpl driven groups. MplP animals had normal PLT counts compared to the GFP control 
group whereas the SF group had lower PLT counts during whole observation time (*P < 0.0004, t-test, two tailed, unequal 
variations). The MplP promoter avoids side effects of ectopic Mpl expression.  
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Interestingly, these were the groups with the low expressing promoters, leading to the 
assumption of graft failure from too high expression of Mpl as in the SF group or from 
lacking Mpl expression as in the SIN.SF.GFP control group.  
We then performed the same BMT experiment, but the recipient mice received 200,000 
Mpl-/- competitor cells. We compared the potential of the three gamma-retroviral SIN 
vectors containing the internal promoters SF, PGK and MplP: SIN.MplP.wtMpl (n=5), 
SIN.PGK.wtMpl (n=5), SIN.SF.wtMpl (n=5) and as a control the SIN.SF.GFP (n=5) 
vector construct (Exp. 12). Lin- Mpl-/- BM cells were transduced and transplanted with 
the competitors to ensure efficient short-term engraftment. Two animals died after only 
two weeks of engraftment failure (SIN.SF.wtMpl, SIN.SF.GFP). However, all other 
animals (18/20) survived long-term. Regular measurements of the PB cell parameters 
showed that there were no alterations in hematopoiesis over time for all constructs in 
WBC and RBC (Figure 3.23D). Interestingly, PLT counts of the SF group were 
statistically significantly lower (*P < 0.0004, t-test, two tailed, unequal variations) during 
the whole observation time compared to the MplP group which stayed in the normal 
range for PLT counts compared to the GFP group (Figure 3.23D). Transgene-positive 
cells of either construct driven by the SF, PGK or MplP promoter were hardly detected in 
the PB by flow cytometry. To conclude, transduced Mpl-/- cells could engraft Mpl+/+ mice 
after BMT. The Mpl-transduced cells had a slight growth advantage compared to 
untransduced Mpl-/- cells (Figure 3.23B), by decreasing CD45.2 cells, similar to that seen 
in Chapter 3.1. Mpl expression by MplP left hematopoiesis unchanged whereas the SF-
driven Mpl expression showed reduced PLT counts most likely due to ectopic 
overexpression of the transgene. 
 
3.3.6. Mpl gene-corrected Mpl-/- bone marrow cells contribute to the LSK 
fraction after BMT 
CD45.2 (donor) positive cells were found in the PB and in the BM fraction (Figure 
3.24A, Exp. 12). To confirm the vector integration we determined the vector copy 
number via qPCR in the genomic DNA of the whole BM. After correction for CD45.2 
positive cells in the BM (black) when available or alternatively in the PB (red) we found 
relevant gene marking in all animals (Figure 3.24B).  
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Figure 3.24: Gene marking and histology. (A) Flow cytometry data of BM (black) and PB (red) measurements of 
CD45.2 (donor) positive cells in Mpl+/+ animals transplanted with SIN transduced Mpl-/- BM cells by final analysis. The 
animals showed reduced CD45.2 positive cells in the BM compared to the CD45.2 positive cells in the PB. The CD45.2 
fraction was not analyzed in the BM in the following animals: SIN.MplP.Mpl 2, 3, SIN.PGK.Mpl 2, 3, 5, SIN.SF.Mpl 4 
and SIN.SF.GFP 1, 2. (B) The vector copy number in the BM of animals receiving retrovirally transduced BM cells was 
determined by qPCR. Values from whole BM were corrected for the CD45.2 positive fraction in the BM (black) when 
available or in the PB (red). All animals showed relevant gene marking in the transduced Mpl-/- cells. (C, D, E) 
Histopathology analysis of SIN.SF.wtMpl transplanted mice from Exp. 10 shows dysplasia in the histopathology. The BM 
(C) shows increased mast cell proliferation. The liver (D) and the spleen (E) have no abnormalities. Magnification and 
staining: (C) Giemsa, 200x, (D, E) Giemsa, 100x. 
 
Interestingly the gene marking for the SIN.SF.GFP transduced cells was the lowest 
compared to the other constructs which might be due to the absence of Mpl-/- correction.  
The expression of Mpl by the MplP was difficult to measure in the PB due to the 
differentiation-specificity or to the low expression. However, Mpl expression will be 
higher in the HSC compartment therefore we determined the RNA expression level of 
endogenous Mpl in different cell fractions of the BM of WT mice. GMP, CMP, MEP, 
MPP (multipotential progenitor), LT (long-term HSC), ST (short-term HSC) fractions 
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were analyzed via qPCR in one experiment and Mpl expression in the GMP fraction was 
set to one (Figure 3.25A). We found the highest expression of Mpl in LT cells with nearly 
1900 times increase compared to GMP. Also, MPP (760-fold) and ST cells (116-fold) 
had higher amounts of Mpl RNA than the GMP fraction. All together the highest 
expression of Mpl in steady state hematopoiesis was in the LSK fraction resembling 
MPP, LT and ST fractions where we decided to measure the transgene expression 
mediated by the MplP. 
Flow cytometry analysis of Exp. 10 showed that untransduced Mpl+/+ cells can fully 
engraft Mpl+/+ mice (n=2) after BMT. The LSK compartment (Figure 3.25B, first blot) 
was mainly comprised of CD45.2 donor cells (Figure 3.25B, second blot). However, 
untransduced Mpl-/- cells were hardly detected at final analysis after 12 months in the 
LSK fraction (n=4) (Figure 3.25B, third blot). Here, most of the cells in the LSK fraction 
were derived from the recipient (CD45.1). Importantly, SIN.SF.wtMpl gene-corrected 
Mpl-/- cells could be detected in the LSK fraction after BMT into Mpl+/+ mice (Figure 
3.25B, fourth blot, Exp. 10). Here most of the cells were derived from the donor animal 
and were CD45.2-positive (82.3%) and also wtMpl-positive (13.5%). Not all CD45.2+ 
cells seemed to be transgene-positive. It may be possible that the expression of the Mpl 
transgene in the CD45.2 cells was so low that it could not be efficiently detected by 
FACS staining and therefore CD45.2 cells may appear false-negative. 
In another experiment (Exp. 12), following the same setup, Mpl+/+ animals were 
transplanted with SIN.MplP.wtMpl, SIN.PGK.wtMpl, SIN.SF.wtMpl and SIN.SF.GFP 
Lin- Mpl-/- BM-transduced cells. Again, wtMpl-positive cells were detected for 
SIN.MplP.wtMpl (14.4%) transduced cells in the LSK fraction by final analysis after five 
months observation time (Figure 3.25C). Also, transgene-positive cells for the other 
promoter-driven constructs were found in the LSK fractions with the SF (8.1%) promoter 
(Figure 3.25D) and the PGK (9.3%) promoter (Figure 3.25E). Surprisingly for the GFP-
expressing group, GFP (10.2%) positive CD45.2 positive Mpl-/- cells were also found 
(Figure 3.25F). This is most likely due to a shorter observation time (5 months) compared 
to the Exp. 10 (12 months) where no CD45.2 cells could be seen without Mpl 
transduction.  
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Figure 3.25: LSK fraction analysis. (A) RNA was prepared from sorted cell fractions of wild type mice and analyzed for 
endogenous Mpl expression after RT-PCR in the qPCR. Values were calculated after the comparative CT method. Fold 
expression of fractions is shown compared to GMP (granulocyte monocyte progenitor) cells which was set to one. CMP 
(common myeloid progenitor), MEP (megakaryocyte erythroid progenitor), MPP (multipotential progenitors), ST (short 
term HSC), LT (long term SHC) built the analyzed fractions. The last three fractions (MPP, LT and ST) belong to the LSK 
(Lin-, Sca1+, ckit+) fraction which represents the highest amount of Mpl RNA in the BM of steady state hematopoiesis in 
wild type mice (one experiment measured in triplicates). (B) FACS blots from CD45.1 WT mice transplanted with 
transduced or untransduced CD45.2 Mpl-/- and WT CD45.2 BM cells from Exp. 10 are shown. First blot represents the 
LSK fraction. Second blot is a WT CD45.1 mouse which received WT untransduced BM cells. All LSK cells originated 
from the donor. The third blot shows one animal which received untransduced Mpl-/- BM cells for transplantation. Almost 
all LSK cells originated from the recipient mouse. The last blot shows one animals which received SIN.SF.wtMpl 
transduced Mpl-/- BM cells. Here most of the cells in the LSK fraction originated from the donor and some were transgene 
positive. (C) Mpl transgene positive cells could also be found with the MplP expressing construct. All the other promoter 
driven constructs, SF (D), PGK (E) and the GFP expressing control group (F) showed transgene positive cells in the LSK 
fraction. (G) The first graph shows the mean ± SD of transgene positive cells in the LSK fraction. The second graph 
represents the mean of all animals for the LSK fraction in the whole BM sample. The third graph displays the donor 
positive fraction CD45.2 in the LSK fraction. MplP n=5, PGK n=4, SF n=3, GFP n=2.  
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Taking all mice from Exp. 11 and 12 together, we found the highest number of wtMpl-
expression in Mpl-/- cells transduced with the SIN.MplP.wtMpl (mean n=5: 8.3%) vector 
(Figure 3.25G, first graph). This leads to the conclusion that Mpl expression under the 
control of the MplP was close to the physiological expression level compared to SF 
(mean n=3: 4.6%) and PGK (mean n=4: 4.8%) promoter-driven vectors. This may have 
resulted in a positive selection advantage of MplP-transduced cells compared to the Mpl 
expression before transplantation (MplP: 4.0%, PGK: 51.0%, SF: 36.0%) seen in Table 
3.5, Exp. 12. The MplP-driven group received about 10 time less Mpl positive cells as 
detected by flow cytometry. However, after BMT the MplP-driven group presented with 
the highest amount of transgene positive cells in the LSK fraction (Figure 3.25G, first 
graph). The MplP-driven group also showed the highest amount of LSK (mean, MplP: 
0.8%, PGK: 0.4%, SF: 0.5%)-positive cells (Figure 3.25G, second graph) by similar 
amounts of CD45.2 (mean, MplP: 39.6%, PGK: 64.0%, SF: 56.4%) cells in the LSK 
fraction compared to the other vectors (Figure 3.25G, third graph). Taken these results 
together with the vector copy number from Mpl transduced and GFP transduced cells 
(Figure 3.24B) the data support the hypothesis of a selection advantage for the 
SIN.MplP.wtMpl vector in the Mpl-/- background.   
All mice stayed macroscopically healthy during the whole observation time. However, 
animals receiving the SF or the PGK promoter driven vectors showed slight dysplasias in 
the BM with increased mast cell proliferation (Figure 3.24C, D, E), similar to the MDS-
like disorder seen in Chapter 3.1. Interestingly these symptoms were absent in the MplP-
driven group. To conclude, the MplP-driven construct shows very promising results in 
long-term reconstitution of lethally irradiated Mpl+/+ mice with gene-corrected Mpl-/- 
cells. PB data did not change during the whole observation time and mice showed no 
signs of disease after histopathologic analysis. Cells expressing wtMpl via the MplP seem 
to have a positive selection advantage compared to SF or PGK promoter-driven 
transgene-expressing constructs most likely due to physiological expression levels and 
differentiation specificity. This vector construct should mediate a clear therapeutic effect. 
However, this is still to be shown in BMT experiments with Mpl-/- cells into Mpl-/- 
recipients.  
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3.3.7. SIN vector architecture can reduce the risk of malignant clonal 
dominance  
To address the question whether self-inactivating vector architecture has advantages 
compared to LTR-driven vectors regarding insertional mutagenesis, we compared the 
diagnosis of all SIN vector Mpl-expressing animals with the LTR animals. Mice 
receiving SIN vectors (in Mpl+/+ and Mpl-/- background) should have a lower 
susceptibility to insertional mutagenesis resulting in leukemia compared to LTR-driven 
retroviral vectors (Modlich et al., 2006; Modlich et al., 2008). In total we transplanted 31 
(Exp. 9 – 12, Table 3.5) mice with SIN vectors harboring different internal promoters and 
the wtMpl transgene. None of the animals developed leukemia despite relevant gene 
marking (Figure 3.21B and Figure 3.24B) compared to the LTR-driven vectors where 
3/27 mice developed vector-derived leukemias, as shown in Chapter 3.1. From the in vivo 
studies, we can conclude that the risk of leukemia development seen with the LTR-driven 
vectors (3/27 mice) is reduced in the SIN vector constructs (0/31). However, cell culture 
models to determine the replating frequency of the SIN vector constructs should be 
performed to further analyze the genotoxic risk (Modlich et al., 2006; Zychlinski et al., 
2008).  
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4.1. Gene therapy for Mpl deficiency is a challenge which can be overcome 
The development of a gene therapy for Mpl deficiency is a completely novel strategy to 
cure CAMT. The only therapy which can be used today is allogeneic BMT. In three 
previous studies, Mpl was retrovirally overexpressed in the murine BM: Yan et al. found 
an increase of erythropoiesis with subsequent leukopenia and thrombocytopenia (Yan et 
al., 1999), similar to our study. However, they did not experimentally address the 
involvement of primitive hematopoietic cells in disease progression nor perform studies 
to directly address the dominant negative effect of ectopic Mpl on unmodified bystander 
cells nor the role of transgene expression levels. Others described the development of a 
myeloproliferative disease (MPD) when using replication-competent Mpl-expressing 
retrovirus (Cocault et al., 1996). The third study found no effects on HSC differentiation 
using the human MPL in a mouse model (Goncalves et al., 1997). We demonstrated that, 
dependent on vector design, the expression level of Mpl heavily influences the 
experimental outcome. Even the relatively weak PGK promoter did not prevent severe 
adverse events of retroviral Mpl expression. In contrast, optimized vectors that express 
Mpl from its endogenous promoter (MplP) induced no alterations in hematopoiesis, 
despite substantial vector gene marking in the BM and long-term observation. The 
potential therapeutic benefit could be shown in Mpl-/- BM in vitro and by transplanting 
animals with Mpl-corrected Mpl-/- BM cells. The risk of side effects from insertional 
mutagenesis were observed and prevented. Also, a possible use of redesigned MPL 
protein receptors for therapeutic applications was investigated. To conclude, gene therapy 
of MPL deficiency might be possible for patients suffering from CAMT despite the small 
therapeutic window.  
 
4.2. Cytopenias involving the MPL receptor or its ligand THPO 
When transplanting mice with cells transduced with the high Mpl-expressing vector 
constructs, most animals developed a severe pancytopenia involving the whole 
hematopoiesis. MPL and THPO deregulation is seen in many human diseases. Patients 
with aplastic anemia and thrombocytopenia have elevated THPO levels similar to that 
seen in our animal model (Ichikawa et al., 1996; Mukai et al., 1996). Diamond-blackfan 
anemia presents with increased THPO levels, possibly with an attempt to compensate for 
 
 
 
Discussion   
101 
101
impaired erythropoiesis (Pospisilova et al., 2004). HIV-infected patients have 
significantly elevated MPL receptor levels on the platelet surface and elevated THPO 
serum levels which can result in thrombocytopenia (Sundell and Koka, 2006). 
Thrombocytopenia is also a problem in patients with liver cirrhosis. MPL expression 
levels on platelets are significantly reduced in cirrhotic patients and seem to correlate 
with the development of the disease (Ishikawa et al., 2002). Because the liver is the major 
production site of THPO there may be a connection from cirrhosis and MPL deregulation 
via THPO, which then correlates with a poor disease prognosis. Following this idea, 
anemia and thrombocytopenia in liver cirrhotic patients may result from THPO/MPL 
deregulation.  
Recently, the influence of the MPL receptor expressed on endothelial cells was 
investigated. However, the amount of receptor did not contribute to the regulation of 
circulating THPO levels (Geddis et al., 2006). The model of soluble cytokine receptors 
(Heaney and Golde, 1996) leading to a dominant negative effect, like circulating 
antibodies, may also be true for MPL. Naturally occurring truncated forms of the MPL 
receptor are known, possibly caused by alternative splicing (Millot et al., 2002). 
Truncated isoforms of Mpl with essential C-terminal peptides target the full-length 
receptor for degradation and might be a new mechanism for receptor regulation (Coers et 
al., 2004; Sabath et al., 2002). It is also known that cytoplasmic Mpl receptors can 
transfer signals like the membrane-bound ones (Otto et al., 2001). Increased numbers of 
these soluble forms can also be the reason for thrombocytopenia. 
Patients treated with recombinant human THPO (rhTHPO) developed THPO-specific 
antibodies that also acted against endogenous THPO. Their hematopoietic system was 
severely affected and they eventually developed pancytopenia (Basser et al., 2002; Li et 
al., 2001). The dominant negative effect conducted by the anti-THPO antibodies is 
similar to that found in our experiments and results in similar phenotypes. This side effect 
observed in patients confirms that deregulation of THPO signaling has profound effects 
on humans. Of note, genetic deficiency of MPL also has a much more striking effect on 
humans than on mice, since all CAMT patients with a complete absence of MPL develop 
aplastic anemia in early childhood (Germeshausen et al., 2006), in contrast to the more 
subtle HSC defect observed in Mpl-deficient mice (Alexander et al., 1996c; Kimura et al., 
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1998; Petit-Cocault et al., 2007). We thus postulate that disturbing the regulation of MPL 
expression in patients may also lead to profound effects involving the regulation and 
regeneration of the HSC pool. In agreement with that, in preleukemic and leukemic 
situations, the unregulated expansion of cells that express MPL or other receptors that 
may sequestrate a crucial niche factor, may contribute to the selective displacement of 
normal hematopoiesis and further aggravate the disease. 
 
4.3. CMPD and MDS are clonal events in humans and often show 
deregulation of MPL or THPO  
It is important to point out that in our mice developing CMPD and MDS-like disorders no 
selection for a single transformed clone occurred. Therefore – although the symptoms 
mimic the respective human pathologies – they do not completely resemble the human 
pathogenesis. However, recent calculations for clonal dominance in mice suggesting the 
transformation of one HSC estimate 2.5 ± 0.5 years latency for clonality in contrast to an 
expected lifespan of a maximum of two years (Catlin et al., 2005). In our murine model, 
ectopic Mpl expression alone is sufficient to induce those pathologies, thus abrogating the 
need for clonal selection in the pathogenesis of CMPD and MDS.  
CMPD is characterized by excessive hematopoiesis which results from one or more 
hematopoietic growth factors (Kaushansky, 2006a). In our experiment, CMPD was 
caused by the overexpression of the Mpl receptor on non-target cells. In human CMPD, 
Mk and erythroid cells exhibit increased Mpl expression levels (Bock et al., 2004) and 
abnormal megakaryopoiesis is frequently found in the BM (Duensing et al., 1999). Some 
patients with CMPD develop acute transformation of blasts with megakaryocytic features 
similar to our model (Hashimoto et al., 2000). In familial essential thrombocythemia, 
platelets are strongly increased. This is determined in the upregulation by the 
hematopoietic growth factor THPO which is caused by a mutation in the promoter region 
of the THPO gene (Kondo et al., 1998).  
The role of THPO signaling in human MDS is largely unknown. Because one typical 
feature of MDS is abnormal megakaryopoietic development and thrombocytopenia, some 
studies have focused on  the expression of MPL and THPO in MDS patients (Adams et 
al., 1997; Hofmann et al., 1999). In MDS, deregulation of THPO levels (up- or down 
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regulation depending on the involved population) were found (Emmons et al., 1996; 
Ichikawa et al., 1996; van den Oudenrijn et al., 2002) while expression levels of MPL 
were unchanged or lowered (Tamura et al., 1998). In addition, the intracellular signal 
transduction of THPO signals appeared to be altered. STAT3 and STAT5 activation was 
enhanced in CD34 cells in the late phase of MDS progression (Kalina et al., 2000). 
Dysmegakaryopoiesis in MDS patients could not be treated with addition of THPO 
(Hofmann et al., 2000). Inadequate THPO response in MDS patients possibly results 
from overexpression of MPL on the preleukemic clone leading to a dominant negative 
effect (Zwierzina et al., 1998).  
The Mpl receptor is expressed on murine mast cells and deletion of Thpo increases mast 
cell proliferation (Martelli et al., 2008; Migliaccio et al., 2007). THPO alone also 
supports mast cell growth from human hematopoietic progenitor cells (Kirshenbaum et 
al., 2005) which could explain the excessive mast cell proliferation in our model. 
Osteosclerosis, similar to our case, was also found in mice overexpressing Thpo which 
could be reduced with proteasome inhibitors (Villeval et al., 1997; Wagner-Ballon et al., 
2007). Nevertheless, it may be worthwhile investigating consumption of crucial niche 
factors, other than THPO, by aberrant cell clones as a confounding factor of human MDS. 
Competition for microenvironmental support can lead to the suppression of normal 
hematopoiesis (Catlin et al., 2005). Recently, a potential new ligand for the MPL receptor 
was found. The human homologue of a fungal nuclear migration protein (hNUDC) was 
shown to bind to the extracellular domain of MPL and activate proliferation of Mk and 
platelets (Pan et al., 2005; Wei et al., 2006). Consequently, factors which were not 
brought into sight of MPL interference so far could also be responsible for CMPD and 
MDS in patients.  
 
4.4. Hematopoietic population crisis induced by Mpl overexpression 
resembles gradation effect in population ecology 
In previous work, the study of hematopoietic cytokine receptor expression has mostly 
focused on cell-intrinsic effects regulating cell survival, differentiation and 
transformation. We chose ectopic expression of Mpl by gamma-retroviral vectors in a 
competitive BMT model to address both cell-intrinsic and population effects of ectopic 
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receptor expression. We demonstrate that Mpl-overexpressing hematopoietic cells acquire 
an initial growth advantage with massively elevated multi-lineage hematopoiesis 
resembling CMPD with proliferation of blasts in extramedullary sites. From this stage of 
hyperproliferative hematopoiesis, two different outcomes occurred. A minority of animals 
(~10%) developed erythroid leukemia, which was dependent on secondary events such as 
the retroviral insertion sites in known proto-oncogenes encoding transcription factors. In 
the majority of mice, however, the CMPD resulted in a fatal population crisis, leading to 
lethal pancytopenia with crucial aspects of MDS. As unmodified hematopoietic cells 
were also involved in the population crisis, and a dominant-negative Mpl receptor 
expressed in a chimeric situation induced the same phenotype, we hypothesize that 
consumption of a crucial niche factor, e.g. Thpo, was the major cause of the population 
crisis.  
Recent reports define the function of THPO signaling in the maintenance of HSC 
quiescence (Qian et al., 2007; Yoshihara et al., 2007). These studies suggest that the 
depletion of THPO results in higher HSC cycling with potential exhaustion. Analysis of 
the stem and progenitor cells in mice during the different stages of disease progression in 
our study showed an augmentation of CMP, GMP and MEP shortly after transplantation 
and reduction of LSK as well as CMP, GMP and MEP cells during pancytopenia 
development, whereas mice expressing the dominant negative receptor lacked the early 
increase of hematopoiesis. Even prior to the onset of pancytopenia, we could show in 
CFU assays of wtMpl-transplanted mice that BM cells of these animals showed a 
significantly reduced colony formation capacity compared to GFP-expressing cells. All 
these phenotypes involved co-existing unmodified cells, arguing against a predominant 
role of cell-intrinsic effects such as exhaustion in the development of pancytopenia and 
MDS.  
The successive rise and fall of hematopoiesis induced by overexpression of Mpl on a 
subset of cells perfectly matches the phenomenon of gradation in population ecology, 
with a phase of rapid population expansion addressed as progradation, until the peak of 
the population (culmination) occurs with a subsequent decline addressed as retrogradation 
(Schwerdtfeger, 1932; Stoecker and Dietrich, 1986). The term gradation, originally used 
in the context of population ecology, can describe the progression seen in our model from 
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CMPD (progradation) to pancytopenia and MDS (retrogradation) after ectopic expression 
of Mpl on a subset of BM cells (Figure 4.1). To our knowledge, this striking transition 
from cell-intrinsic to population effects is unprecedented in studies addressing the role of 
cytokine receptors. We would therefore suggest to include population dynamics as an 
important readout in future studies addressing the role of cytokines and their receptors in 
tightly balanced regenerative systems such as hematopoiesis.  
 
Figure 4.1: Schematical description of the population effect (adapted from Stoecker and Dietrich, 1986). Cell counts 
of hematopoiesis rise during progradation phase which resembles CMPD in mice some weeks after transplantation with 
wtMpl transduced BM cells. When a crucial niche factor (e.g. Thpo) is exhausted, HSC reduce proliferation and 
differentiation. Cell counts of PB start to decrease. When sequestering effects are too high cell counts of all hematopoietic 
lineages are reduced below normal hematopoiesis level. Mice then turn into retrogradation phase which we could describe 
as pancytopenia with MDS. The rise and fall of hematopoiesis resembles the gradation effect used in ecology for many 
years to describe the progradation and retrogradation phases of a whole animal species (especially insects) to describe their 
dependence on nutrition and other ecologic factors resulting in high population rates with subsequent decrease after niche 
factors are exhausted. 
 
4.5. The adaptive mechanism of THPO and MPL influences hematopoietic 
stem cells 
In our experimental system involving hematopoietic cells of regular C57Bl6/J mice, the 
expression of Mpl under the control of a retroviral LTR resulted in an unrestricted 
expression in all major hematopoietic lineages. In contrast, endogenous MPL starts to be 
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expressed in HSC and is then restricted to the megakaryocytic lineage and platelets which 
regulate THPO levels in the periphery. HSC reside in their special niche in the BM (Yin 
and Li, 2006) and chemokine-mediated interaction, in addition to THPO/MPL, of 
hematopoietic progenitors with the BM niche is required for thrombopoiesis (Avecilla et 
al., 2004). THPO/MPL signaling increases HSC proliferation and self-renewal (Seita et 
al., 2007; Tong et al., 2007; Yagi et al., 1999). Mpl-/- mice have reduced numbers of HSC 
because of defective stem cell amplification and self-renewal (Petit-Cocault et al., 2007). 
Mpl might support early expansion of differentiating stem cells but is not regulating the 
HSC numbers (Abkowitz and Chen, 2007). THPO induces HoxA9 nuclear transport in 
immature hematopoietic cells and stimulates HoxB4 expression (Kirito et al., 2003; 
Kirito et al., 2004) which could be a potential mechanisms by which THPO supports 
HSC. The discovery that a diverse range of transcription factors are downstream effectors 
of THPO helps to explain the molecular mechanisms by which the cytokine affects 
hematopoiesis (Kirito and Kaushansky, 2006). As THPO is constitutively produced in the 
liver and in the kidneys, intact megakaryopoiesis and high platelet levels are likely to 
reduce the availability of THPO in the BM niche (Kaushansky, 2006b). This creates a 
feedback in the regulation of HSC survival and expansion, which is dependent on MPL 
expression. Strikingly, if Thpo/Mpl signaling is disabled by targeted genetic knock-out in 
mice, the phenotype is much less severe than the one obtained in our model by 
unregulated overexpression of either wtMpl or dnMpl. This suggests the existence of 
adaptive mechanisms of HSC survival as demonstrated by studies in which Mpl knock-
out cells engraft and repopulate equally efficiently as wild-type BM cells when 
transplanted in a Thpo-deficient background (Abkowitz and Chen, 2007). However, such 
adaptive mechanisms appear to be unavailable or insufficient if Thpo/Mpl homeostasis is 
perturbed in adult wild type animals as in our studies.  
 
4.6. Activating MPL mutants can induce proliferative disorders in patients: 
MPD and leukemia 
Inadequate THPO levels may serve as an in vivo myeloid leukemic growth factor in a 
significant number of AML patients (Corazza et al., 2006). In AML cells, MPL was 
shown to be overexpressed on leukemic blasts and expression levels correlated with poor 
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prognosis from a potential dominant negative effect (Albitar et al., 1999; Schroder et al., 
2000; Wetzler et al., 1997). Recently, activating mutations in the human MPL gene have 
been identified in a subset of MPD patients that were negative for JAKV617F mutations 
(Pardanani et al., 2006; Pikman et al., 2006). Intracellular crucial regions for point 
mutations in the MPL receptor are known which can give rise to constitutive activation 
(Staerk et al., 2006). MPD are grouped in several disorders, some of which emanate from 
receptor mutations like MPLW515LK (Tefferi and Gilliland, 2007). Constitutive MPL 
activation leads to JAK-STAT activation and supports the concept of constitutive JAK-
STAT signaling in human MPD. MPL may even play a role as part of an autocrine 
pathway in MPD (Kaushansky, 1998). In addition, THPO overexpression can lead to 
supraphysiological signaling resulting in similar disorders in mice (Villeval et al., 1997) 
as also seen in our model.  
To address the importance of one other major pathway in MPL-induced leukemia seen 
with the MPLW515LK mutation, we analyzed the Raf-Ras-MAPK-ERK1/2 pathway. 
Mutated NRAS can function as an initiating oncogene by inducing myeloid malignancies 
in mice (Parikh et al., 2006). Oncogenic HRAS promotes abnormal proliferation of CFU-
E progenitors and early erythroblasts and supports their erythropoietin (Epo)-independent 
growth (Zhang et al., 2003) which we also observed in vitro with our caMpl mutant. 
Furthermore, oncogenic KRAS in hematopoietic cells initiates a rapidly fatal 
myeloproliferative disorder (Braun et al., 2004). These pivotal features of increased RAS 
signaling lead us to the hypothesis that RAS is the major pathway for leukemia 
development in constitutively active Mpl. Following this assumption, a truncated Mpl 
receptor that could not activate the Ras signaling pathway was not leukemogenic in our 
experiments, which confirmed our hypothesis.  
Other pathways, like PI3K signaling, are also crucial to many aspects of cell growth, 
survival and apoptosis, and their constitutive activation has been implicated in both the 
pathogenesis and the progression of a wide variety of neoplasias (Martelli et al., 2006). 
Furthermore, acquired activating mutations in JAK-STAT signaling other than 
JAKV617F are involved in the pathophysiology of hematological malignancy (Khwaja, 
2006). It is thus of great interest to perform detailed analysis on these pathways 
downstream of Mpl. Small molecule inhibitors (Pardanani et al., 2007) and peptide 
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agonists of THPO (Cwirla et al., 1997; Erickson-Miller et al., 2005) are tested for 
possible clinical application in MPD resulting from activating mutations in MPL. These 
products can become very potent therapeutics in future as therapeutics for MPD where 
MPL is involved. 
In human gene therapy the risk for the patients to develop an MPD-like disorder from a 
constitutive active mutation is very low. In our mouse model we transplanted BM cells 
where the majority of these cells was transduced with the caMpl mutant resulting in a fast 
outgrowth of leukemia. Despite the low possibility to gain a point mutation in one of the 
critical regions of the MPL receptor, additionally only one cell would carry this mutation 
and had to undergo selection to become a transformed clone. 
 
4.7. The proto-oncogene Mpl is not leukemogenic per se 
In our study, only three out of 27 mice developed acute leukemia with an unusual 
erythroid phenotype. 0/31 mice transplanted with wild-type Mpl receptor in the SIN 
vector backbone harboring high expressing promoters (SF) or low expressing promoters 
(PGK, MplP) developed leukemia. SIN vectors and vectors with low expressing 
promoters have a greatly reduced risk to activate neighboring proto-oncogenes by 
insertional mutagenesis (Ryu et al., 2008; Zychlinski et al., 2008). This indicates that 
enhanced Mpl signaling determines the leukemic phenotype but is not the exclusive 
factor for leukemia induction. In addition, the selection of the specific leukemogenic 
clones strongly supports the finding that insertional activation of proto-oncogenes by 
retroviral vector integration was a necessary cofactor. The selection of clones with 
retroviral vector insertions in the ETS transcription factors Fli-1 or Sfpi-1 (Pu.1) is 
reminiscent of the pathogenesis of erythroleukemia induced by the friend murine 
leukemia virus or the friend virus complex, the latter involving a replication-defective 
virus expressing a glycoprotein, gp55, that stimulates the Mpl-related receptor for 
erythropoietin (EpoR) (Paul et al., 1991; Schuetze et al., 1993; Starck et al., 1999). The 
transcription factor Klf3, which plays a pivotal role in erythroid cell differentiation 
(Funnell et al., 2007), is shown to be deregulated after retroviral insertion in vitro 
(Kirberg et al., 2005).  
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4.8. Conclusion 
In conclusion, we showed that ectopic and unregulated expression of Mpl leads to severe 
deregulation of hematopoiesis. By expression of a dominant negative Mpl receptor that 
can bind but not transfer Thpo signals, we could show that Mpl expression inhibits Thpo 
signaling by a dominant negative effect. An initial, CMPD-like increase of peripheral 
blood cell counts was restricted to the full-length receptor and therefore induced by Mpl 
signaling. However, ectopic Mpl expression was not leukemogenic per se. Our results 
highlight the importance for regulated expression of Mpl, and as such probably for many 
molecules involved in hematopoietin receptor signaling. This has strong relevance for the 
development of gene therapies for hematopoietic disorders that are based on deficiencies 
in hematopoietin receptor signaling molecules.  
In addition, we showed that the expression of a constitutively active Mpl receptor 
mutant is highly leukemogenic. Mice developed erythroid- and myeloid leukemias with 
massive hepatosplenomegaly and strong infiltration in hematopoietic organs. Some 
human MPD are closely connected to MPL mutants that makes research for THPO/MPL 
inhibiting targets an up-to-date topic. Downstream MPL signaling inhibitors may be 
potential therapeutics for Mpl-induced diseases. We showed that truncated receptor 
mutants lacking defined domains that activate signaling pathways of Mpl, like Ras 
signaling, are less mutagenic. Mice did not develop leukemia despite constitutive activity.  
Thirdly, the determination of the underlying mechanisms that cause pancytopenia 
and leukemia lead the way to new vector design. Using the MplP in SIN constructs were 
shown to mediate physiological expression levels and lack the pathogenic side effects. 
We further showed that Mpl-/- BM cells transduced with these new vectors could 
successfully repopulate mice after BMT and participate in hematopoiesis. This is a great 
step towards a therapeutic gene therapy for Mpl deficiency.  
 
4.9. Outlook 
We performed a profound molecular and histological analysis of the Mpl-transplanted 
animals and found no side effects and no dysplasias in mice transplanted with 
SIN.MplP.wtMpl-transduced BM cells. However, further analysis of secondary 
transplantations of gene-corrected cells should be performed. It has to be shown that there 
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are no upcoming side effects like leukemia in secondary recipients resulting from further 
stress on the transduced cells. Another important result which the secondary 
transplantation will show is if long-term HSC were transduced and functionally corrected.  
Furthermore, the correction of Mpl-/- BM by BMT into Mpl-/- recipients should be 
shown. Gene-corrected Mpl-/- mice should present normal platelets and HSC numbers. 
Mpl-/- mice have reduced platelet counts and reduced HSC numbers ten-fold. The rescue 
of HSC number with the gene therapy of Mpl-/- mice is the proof-of-principle for gene 
therapy of CAMT with gamma-retroviral or lentiretroviral vectors. This would also be the 
first evidence of the correction of HSC by function caused by a mutated cytokine 
receptor.  
HSC have low cycling rates and reside relatively quiescently in their niche. MLV 
vectors - used in this study - are only able to integrate into dividing cells and gain access 
to the host genome when the nuclear membrane breaks down during mitosis. Lentiviral 
vectors have the advantage of also transducing quiescent cells. By using lentiviral vectors 
it may be possible to target more HSC, which is very important for CAMT gene therapy 
because of the already reduced HSC numbers in patients. An alternative to deal with this 
problem would be an early collection of HSC from patients. The number of HSC is 
reduced at birth and further decreases with disease development, finally leading to an 
aplastic anemia. The continuing reducing numbers of HSC make it difficult for a gene 
therapy approach to target enough HSC in patients already in final stages using retro- or 
lentiviral vectors. With HSC collection shortly after birth, the important HSC for a 
lifetime curative therapy would be very useful. Also new cytokine cocktails are described 
which maintain the HSC ability ex vivo and stimulate the expansion of HSC (Huynh et 
al., 2008; Zhang et al., 2006). A serum-free culture containing SCF, TPO, FGF-1, 
angiopoietin-like 5, and IGFBP2 supports an approximately 20-fold net expansion of 
repopulating human cord blood HSC, a number potentially applicable to several clinical 
processes including HSC transplantation for CAMT (Zhang et al., 2008). 
The differentiation-specific expression of the Mpl promoter fragment could be 
improved. 2 kb is a large size for a promoter compared to the smaller SF and PGK 
promoters (391 bp and 512 bp). Identification of a minimally sized promoter is critical for 
the design of viral vectors in gene therapy. Deletion mutants of the MplP fragment may 
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give insights into the important regions for the promoter activity. It may be possible to 
reduce the size of the MplP and increase the differentiation-specificity even further. 
Geller et al. recently published an algorithm to predict promoter important sites to reduce 
the size of promoters. They showed that shorter promoter fragments in Müller cells 
predicted by their program showed increased mean fluorescence intensity of transduced 
cells by more positive cells (Geller et al., 2008). Another possibility to mediate site-
specific activity is the use of small molecular RNA target sequences (Brown et al., 2007). 
These microRNA target sequences can be recognized by host cell-specific miRNAs 
which then target the viral mRNA for degradation and thereby restrict the expression to 
only a particular cell lineage. This approach could be an alternative if the MplP mediates 
too low expression or if it still is too nonspecific. A stronger ubiquitous promoter like the 
PGK promoter may be used with the RNA target sequence with restricted expression only 
to express receptors in HSC and Mk.  
As described in the literature, CAMT results from inactivating mutations in the c-
mpl gene. These mutations can lead to a block of receptor dimerization or if the mutations 
are in the THPO binding region they can inhibit ligand binding. For patients suffering 
from the latter mutations, an alternative therapy could be considered. Novel small 
molecules which mimetic activities of Thpo can be used. These mimetics specifically 
activate the Mpl receptor and induce increased platelet numbers in mice (Inagaki et al., 
2004). They may also bind to the mutated MPL receptor and activate dimerization even if 
THPO is not able to bind to these sites. Thereby, mimitics can have therapeutic benefits 
compared to direct THPO application. For these specific groups of CAMT patients, 
mimetics might have a therapeutic effect which makes a difficult and risky gene therapy 
approach unnecessary.  
Designing an artificial receptor construct as a therapeutic molecule is another 
approach for gene therapy of CAMT. F36VMpl is such a molecule and induces a 
sustained expansion of mouse BM cells ex vivo and erythroid cells in vivo and also 
induces a response sufficient to accelerate recovery from irradiation-induced anemia 
(Weinreich et al., 2006). The mutant F36VMpl lacks the ability to bind THPO but can be 
activated with CID (chemical inducers of dimerization) which should reduce side effects, 
but also makes it necessary for the patient to take a drug throughout his/her life time 
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without knowing the consequences (Richard et al., 2004). Also, our nrMpl and cnnMpl 
constructs, mediating proliferation of transduced cells but lacking leukemogenic potential 
as the caMpl receptor, could be used to i.e. expand HSC in a transcriptionally regulated 
promoter vector system or when expressed transiently only.  
Finally, a novel strategy for a curative therapy is homologous recombination in 
induced pluripotent cells (iPS). The therapeutic benefit was recently demonstrated in a 
murine model of sickle cell disease (Hanna et al., 2007). It was shown that 
reprogramming of fibroblasts to a pluripotent state could be induced in vitro through 
ectopic expression of four transcription factors (Oct4, Sox2, c-Myc and Klf4). These data 
demonstrate that pluripotent HSC can be directly generated from fibroblast cultures by 
the addition of only a few defined factors (Takahashi and Yamanaka, 2006; Wernig et al., 
2007). The use of iPS cells as a curative approach for many disorders is thinkable, also 
for CAMT. 
All these above-mentioned strategies are novel potential therapeutic options for 
curing MPL deficiency resulting in CAMT. However, more work on safety studies and 
correct dosage finding is needed. This work took the strategy of classical gene therapy 
and showed the advantages as well as the disadvantages of this technique. It could well be 
that in the end the combination of two or more strategies will prove to be successful. 
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6.1. Mpl sequence 
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6.2. Insertion sites of caMpl leukemias (Table 3.4) 
 
 
 
 
 
Appendix   
128 
128
 
 
 
 
 
 
Appendix   
129 
129
 
 T
ab
le
 3
.4
: 
In
se
rt
io
n 
si
te
s.
 L
is
t 
of
 i
ns
er
tio
n
si
te
s
of
 S
F9
1.
ca
M
pl
, 
SF
91
.R
R
E.
ca
M
pl
 a
nd
 S
F9
1.
nt
M
pl
 t
ra
ns
pl
an
te
d
an
im
al
s
(n
=2
6)
. 
Al
l 
an
im
al
s
de
ve
lo
pe
d
le
uk
em
ia
. I
ns
er
tio
n 
si
te
s
w
er
e
de
te
ct
ed
by
LM
-P
C
R
. C
lo
se
st
ge
ne
s 
in
 a
 fr
am
e
of
 p
lu
s-
m
in
us
15
0 
kb
p
fro
m
in
se
rti
on
si
te
ar
e
lis
te
d.
 C
IS
 
co
m
m
on
in
te
gr
at
io
n
si
te
, I
D
D
b
In
se
rti
on
al
do
m
in
an
ce
da
ta
ba
se
, R
TC
G
D
 R
et
ro
vi
ra
lt
ag
ge
d
ca
nc
er
ge
ne
da
ta
ba
se
, d
is
ta
nc
e 
ne
ga
tiv
e 
nu
m
be
r
= 
5’
fro
m
tra
ns
cr
ip
tio
n
st
ar
t s
ite
, d
is
ta
nc
e 
po
si
tiv
e 
nu
m
be
r=
 3
’f
ro
m
tra
ns
cr
ip
tio
n
st
ar
t s
ite
, R
 re
ve
rs
e,
 F
 fo
rw
ar
d.
 
 
 
Appendix   
130 
130
6.3. Danksagung /Acknowledgements 
 
Ganz besonders möchte ich mich bedanken bei meiner Mutter Claudia und meinem Vater 
Peter, die mich die vielen Jahre meiner Ausbildung unterstützt haben und immer an mich 
geglaubt haben. Herzlichen Dank weiterhin an Hannah, die mir immer beigestanden hat 
und durch die die Jahre der Promotion wie im Flug vergingen. Ohne euch wäre ich 
niemals so weit gekommen. 
Besonders bedanken möchte ich mich auch bei meiner Betreuerin Ute Modlich, die mir 
auf all meine Fragen Antwort gab und mir bei allen Aufgaben bereitwillig zur Seite stand. 
Weiterhin möchte ich mich bei meine Kobetreuer Johann Meyer bedanken für seine 
ständige Hilfe und große Bereitschaft seine Erfahrungen mit mir zu teilen. Danke euch 
beiden für kritischen Austausch und die lange Unterstützung. 
Ein besonderer Dank gilt Prof. Christopher Baum, der es mir ermöglicht hat in seiner 
Arbeitsgruppe zu forschen und mich immer unterstützt hat. Vielen Dank für viele 
kritische Diskussionen und fachlichen Rat. 
Ein weiterer Dank gilt Prof. Walter Müller meinem Doktorvater für seine Bereitschaft mir 
auf dem Weg der Promotion zur Seite zu stehen und mir dadurch viel Halt und Vertrauen 
in das Gelingen gegeben hat. 
Vielen Dank auch an Prof. Karl Welte, meinen Korreferenten, für produktive 
Diskussionen und Hilfen. 
Herzlichen Dank an Gill Teicke, die dieses Manuskript auf die englische Sprache geprüft 
hat. 
Sehr bedanken möchte ich mich weiterhin bei allen Personen aus der Experimentellen 
Hämatologie. Ganz speziell möchte ich danken: Axel, der mir viele seiner Vektoren zur 
Verfügung gestellt hat, Sabine und Cindy, die mich handwerklich unterstützt haben, 
Mathias, Thomas und Zhixiong, mit denen ich gemeinsame Zeit mit den Mäusen 
verbracht habe, Bernd für seine bereitwillige Hilfe mich in der Fluoreszenzmessung 
einzuweisen, Hannes für seine ständige Diskussion- und Hilfsbereitschaft, Martijn für das 
Teilen seiner Kenntnisse in statistischen Fragen, Jens Bohne für die Bereitstellung des 
RRE-Vektors, allen weiteren Doktoranden Tobias, Daniela, Melanie, Niels, Dietrich, 
Christine und Stefan durch die die Arbeit nicht nur während der Arbeitszeit sehr schön 
 
 
 
Appendix   
131 
131
war. Danke an die anderen netten Kollegen Marion, Cema, Rita, Elke, Yan Min, Sohila. 
Ihr alle seid ein tolles Team, sowohl während der Arbeit als auch in der Freizeit. Viel 
Erfolg weiterhin dem Doktoranden Club. 
Weiterhin bedanken möchte ich bei Personen aus anderen Arbeitsgruppen, die mich 
freundlicherweise unterstützt haben, wie Guntram Büsche, für seine histopathologischen 
Auswertungen, Matthias Ballmaier, für anregende Diskussionen und Unterstützung am 
Cell Sorter, Martin Hapke, für seine Hilfe bei den Mausversuchen, bei Herrn Frühauf, aus 
der Bestrahlungs-Facility, bei Wolfgang Köstner, für seine immer freundliche 
Hilfsbereitschaft. 
Bedanken möchte ich mich noch für die freundliche und hilfsbereite Aufnahme in 
Cincinnati bei Punam Malik, die mich in ihrem Labor hat forschen lassen und mich 
tatkräftig unterstützt hat, David Williams, der mich herzlich in seiner Abteilung 
aufgenommen hat, bei Ajay Perumbeti und Theodosia Kalfa für ihre große Bereitschaft 
bei experimenteller Hilfe und bei Anjali, die mir die Wirren des Children’s Hospitals 
entwirrt hat. 
 
 
 
 
Appendix   
132 
132
6.4.  Beteiligungen /Contributions 
 
Histopathology: Guntram Büsche 
 
 Chapters: 
 2.3. Mouse experiments and analysis 
 3.1.2. Mpl expression confers a selective 
growth advantage to murine bone marrow cells 
 3.1.3. Leukemias developing in wtMpl 
expressing mice require insertional mutagenesis 
 3.1.6. Pancytopenic mice develop an MDS-like 
bone marrow failure syndrome 
 3.3.3. Differentiation-specific and low Mpl 
expression reduce the risk of side effects in 
mice after BMT 
 3.3.6. Mpl gene-corrected Mpl-/- bone marrow 
cells contribute to the LSK fraction after BMT 
 
 
SKY analysis: Cornelia Rudolph, Tanja Hinrichsen  
  
 Chapters:  
 2.2. Cell culture techniques and analysis 
 3.2.3 caMpl-induced leukemia selects for 
clones with retroviral vector insertions in proto-
oncogenes 
  
 
Lineage Mpl expression level: Ute Modlich, Sabine Knöß 
 
 Chapter:  
 3.3.6. Mpl gene-corrected Mpl-/- bone marrow 
cells contribute to the LSK fraction after BMT 
 
 
Statistical analysis:  Martijn Brugman 
  
 Chapters: 
 2.3. Mouse experiments and analysis 
 3.1.2. Mpl expression confers a selective 
growth advantage to murine bone marrow cells 
 3.1.5. Pancytopenia after transplantation is 
induced by a dominant negative effect 
 
 
 
Appendix   
133 
133
6.5. Lebenslauf / Curriculum Vitae  
 
 
 
Persönliche Daten: Daniel Wicke 
   Mendelssohnstraße 2   Telefon: 0511 / 2352797 
   D-30173 Hannover   E-Mail: danielwicke@gmx.de 
     
     
Geburtsdatum, -ort: 22. November 1977 in Düsseldorf 
Familienstand:  ledig 
 
 
 
Praktika und berufliche Tätigkeiten: 
 
 
 
Seit 02/2005  Medizinische Hochschule Hannover 
   Abteilung Experimentelle Hämatologie 
Promotion, Gentherapie der Mpl Defizienz 
 
 
Seit  09/2006  Firmengründung, dw-websites 
   Scientific Webdesign Hannover 
   Design und Programmierung wissenschaftlicher Webseiten 
 
 
03/2007  - 03/2007 Cincinnati Children’s Hospital Medical Center, USA 
   Department Experimental Hematology 
   Molecular description of caMpl induced erythroid leukemias 
 
04/2004 - 12/2004 Bayer Healthcare AG, Wuppertal 
Abteilung Antiinfektiva/ Virologie 
Diplomarbeit, Herstellung und Charakterisierung von Mutanten des 
Humanen Immundefizienz Virus (HIV) die Resistenz gegen Inhibitoren 
der HIV-Protease vermitteln 
 
 
03/2003 - 04/2003 Bernhard-Nocht-Institut für Tropenmedizin, Hamburg  
Abteilung für Virologie 
Projektarbeit, Etablierung eines High-Throughput Inhibitoren Tests für 
Polymerasen der Flaviviridae Familie 
 
 
03/2002 - 04/2002 Bayer AG, Wuppertal 
Abteilung Pharma Research Antiinfektiva/ Virologie 
   Praktikant, Expression und Aufreinigung viraler Proteine 
 
 
 
 
 
Appendix   
134 
134
 
Studium: 
 
10/1999 - 12/2005 Universität Bielefeld  
Studium der Molekularen Biotechnologie 
15/12/2005   Diplom mit Auszeichnung 
 
04/2001 – 09/2002 Universität Bielefeld 
   Studium der Chemie 
 
07/2003 - 12/2003  University of Sydney, Australien 
   Postgraduate Study Abroad in Molecular Biotechnology 
     
 
Schulbildung und Zivildienst: 
 
08/1998 - 08/1999  Zivildienst beim Deutschen Roten Kreuz,  
Mülheim an der Ruhr 
  
16/06/1998  Abitur an der Luisenschule in Mülheim an der Ruhr 
 
Förderungen: 
 
07/2003 Stipendiat der Westfälisch-Lippischen Universitätsgesellschaft, 
Universität Bielefeld 
 
06/2003   Stipendiat der e-fellows.net GmbH & Co. KG, München 
 
Fremdsprachen: Englisch 
   Latein  
   Französisch und Spanisch (Grundlagen) 
 
 
Persönliche Interessen: Sport, Reisen, Literatur 
 
 
Hannover, 16.06.2008 
 
Daniel Wicke 
 
 
 
 
Appendix   
135 
135
6.6. Publications 
 
Peer Reviewed Articles 
 
Daniel C. Wicke, Johann Meyer, Guntram Buesche, Hans Kreipe, Zhixiong Li, Karl H. 
Welte, Matthias Ballmaier, Christopher Baum, Ute Modlich. Hematopoietic population 
crisis induced by ectopic expression of the thrombopoietin receptor Mpl. Submitted. 
 
Ute Modlich, Axel Schambach, Martijn H. Brugman, Daniel C. Wicke, Sabine Knoess, 
Zhixiong Li, Cornelia Rudolph, Brigitte Schlegelberger and Christopher Baum. Leukemia 
induction after a single retroviral vector insertion in Prdm16 or Evi1. Leukemia, 2008. 
 
 
Meeting Abstracts 
 
Daniel C. Wicke, Johann Meyer, Guntram Buesche, Hans Kreipe, Zhixiong Li, Axel 
Schambach, Matthias Ballmaier, Karl H. Welte, Christopher Baum and Ute Modlich. 
Transcriptonally regulated vectors reduce the risk of serious adverse events in gene 
therapy for Mpl deficiency. 11th Annual Meeting of the American Society of Gene 
Therapy, Boston, USA, 29th May 2008.  
 
Daniel Wicke, Ute Modlich, Johann Meyer, Matthias Ballmaier, Cornelia Rudolph, 
Brigitte Schlegelberger, Karl H. Welte and Christopher Baum. Gene therapy of MPL 
deficiency: a narrow window between pancytopenia and leukemia. 36th Annual Meeting 
of the International Society of Hematology, Hamburg, Germany, 28th September 2007.  
 
Daniel Wicke, Ute Modlich, Johann Meyer, Matthias Ballmaier, Cornelia Rudolph, 
Brigitte Schlegelberger, Karl H. Welte and Christopher Baum. Gene therapy of MPL 
deficiency: a paradigm for gene addition therapy of growth factor receptors. 14th Annual 
Meeting of the German Society of Gene Therapy, Heidelberg, Germany, 19th July 2007. 
 
Daniel Wicke, Ute Modlich, Johann Meyer, Matthias Ballmaier, Cornelia Rudolph, 
Brigitte Schlegelberger, Karl H. Welte and Christopher Baum. Gene therapy of MPL 
deficiency: a paradigm for gene addition therapy of growth factor receptors. 10th Annual 
Meeting of the American Society of Gene Therapy, Seattle, USA, 31th May 2007.  
 
Ute Modlich, Axel Schambach, Daniel Wicke, Sabine Knoess and Christopher Baum. 
Insertional mutagenesis by retroviral self-inacitvating vectors containing the viral SFFV 
promoter. 10th Annual Meeting of the American Society of Gene Therapy, Seattle, USA, 
31th May 2007. 
 
Daniel Wicke, Ute Modlich, Johann Meyer and Christopher Baum. Gene therapy of Mpl 
deficiency: a paradigm for the therapeutic expression of growth factor receptors. 3rd 
Leukerbad Meeting of the European CONSERT, Leukerbad, Switzerland, 03rd February 
2007.  
 
 
 
Appendix   
136 
136
 
Daniel Wicke, Ute Modlich, Johann Meyer and Christopher Baum. Gene therapy of 
CAMT: a difficult balance to cure MPL deficiency. 13th Annual Meeting of the German 
Society of Gene Therapy, Duesseldorf, Germany, 13th July 2006.  
 
Daniel Wicke, Ute Modlich, Johann Meyer and Christopher Baum. Gene therapy of Mpl 
deficiency: a difficult balance. Transatlantic Gene Therapy Retreat, Baltimore, USA, 30th 
May 2006.  
 
 
 
 
 
 
